RiceBran Technologies (RIBT) 10-K 16 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 08, 2018	Jun. 30, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	RiceBran Technologies
Entity Central Index Key	1,063,537
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 15,761,754
Entity Common Stock, Shares Outstanding		18,178,724
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 6,203	$ 342
Restricted cash	775	0
Accounts receivable, net of allowance for doubtful accounts of $8 and $12	1,273	1,094
Inventories
Finished goods	564	795
Packaging	114	138
Deposits and other current assets	519	824
Current assets held for sale	0	4,335
Total current assets	9,448	7,528
Property and equipment, net	7,850	7,025
Other long-term assets, net	63	242
Noncurrent assets held for sale	0	14,050
Total assets	17,361	28,845
Current liabilities:
Accounts payable	765	714
Accrued salary, wages and benefits	773	496
Accrued expenses	741	904
Unearned revenue	75	384
Escrow liability	258	0
Current maturities of long-term debt	4	3,063
Current liabilities held for sale	0	15,801
Total current liabilities	2,616	21,362
Long-term debt, less current portion	12	5,964
Derivative warrant liabilities	0	1,527
Noncurrent liabilities held for sale	0	73
Total liabilities	2,628	28,926
Commitments and contingencies
Temporary equity
Preferred stock, Series F, convertible, 20,000,000 shares authorized, 3,000 shares issued and outstanding	0	551
Total temporary equity	0	551
Equity (deficit) attributable to RiceBran Technologies shareholders:
Common stock, no par value, 50,000,000 shares authorized, 18,046,731 and 10,790,351 shares issued and outstanding	279,548	264,232
Accumulated deficit	(265,128)	(259,819)
Accumulated deficit attributable to noncontrolling interest in discontinued operations	0	(699)
Accumulated other comprehensive loss	0	(4,346)
Total equity (deficit) attributable to RiceBran Technologies shareholders	14,733	(632)
Total liabilities, temporary equity and equity (deficit)	17,361	28,845
Series F Convertible Preferred Stock [Member]
Equity (deficit) attributable to RiceBran Technologies shareholders:
Preferred stock	0	0
Series G Convertible Preferred Stock [Member]
Equity (deficit) attributable to RiceBran Technologies shareholders:
Preferred stock	$ 313	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Accounts receivable, allowance for doubtful accounts	$ 8	$ 12
Equity (deficit) attributable to RiceBran Technologies shareholders:
Preferred stock, shares authorized (in shares)	20,000,000
Common stock, par value (in dollars per share)	$ 0	$ 0
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	18,046,731	10,790,351
Common stock, shares outstanding (in shares)	18,046,731	10,790,351
Series F Convertible Preferred Stock [Member]
Temporary equity
Preferred stock, shares authorized (in shares)	20,000,000
Convertible preferred stock, shares issued (in shares)	3,000
Convertible preferred stock, shares outstanding (in shares)	3,000
Equity (deficit) attributable to RiceBran Technologies shareholders:
Preferred stock, shares authorized (in shares)	3,000
Convertible preferred stock, shares issued (in shares)	0
Convertible preferred stock, shares outstanding (in shares)	0
Series G Convertible Preferred Stock [Member]
Equity (deficit) attributable to RiceBran Technologies shareholders:
Preferred stock, shares authorized (in shares)	3,000
Convertible preferred stock, shares issued (in shares)	630
Convertible preferred stock, shares outstanding (in shares)	630

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Consolidated Statements of Operations [Abstract]
Revenues	$ 13,355	$ 12,982
Cost of goods sold	9,564	9,855
Gross profit	3,791	3,127
Selling, general and administrative expenses	9,888	12,384
Loss from continuing operations before other income (expense)	(6,097)	(9,257)
Other income (expense):
Interest expense	(1,623)	(2,483)
Change in fair value of derivative warrant liabilities	670	1,625
Loss on extinguishment of debt	(8,290)	0
Gain on resolution of Irgovel purchase litigation	0	1,598
Other income	307	563
Other expense	(182)	0
Total other income (expense)	(9,118)	1,303
Loss from continuing operations before income taxes	(15,215)	(7,954)
Income tax benefit	5,030	1,824
Loss from continuing operations	(10,185)	(6,130)
Income (loss) from discontinued operations, net of tax	3,983	(5,120)
Net loss	(6,202)	(11,250)
Less - Net loss attributable to noncontrolling interest in discontinued operations	(1,671)	(2,720)
Net loss attributable to RiceBran Technologies shareholders	(4,531)	(8,530)
Less - Dividends on preferred stock, beneficial conversion feature	778	551
Net loss attributable to RiceBran Technologies common shareholders	$ (5,309)	$ (9,081)
Basic earnings (loss) per common share:
Continuing operations (in dollars per share)	$ (0.92)	$ (0.72)
Discontinued operations (in dollars per share)	0.47	(0.25)
Basic loss per common share - RiceBran Technologies (in dollars per share)	(0.45)	(0.97)
Diluted earnings (loss) per common share:
Continuing operations (in dollars per share)	(0.92)	(0.72)
Discontinued operations (in dollars per share)	0.47	(0.25)
Diluted loss per common share - RiceBran Technologies (in dollars per share)	$ (0.45)	$ (0.97)
Weighted average number of shares outstanding:
Basic (in shares)	11,923,923	9,338,370
Diluted (in shares)	11,923,923	9,338,370

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Consolidated Statements of Comprehensive Loss [Abstract]
Net loss	$ (6,202)	$ (11,250)
Other comprehensive income - foreign currency translation, net of tax	184	775
Comprehensive loss, net of tax	(6,018)	(10,475)
Less - Comprehensive loss attributable to noncontrolling interest, net of tax	(1,614)	(2,488)
Total comprehensive loss attributable to RiceBran Technologies shareholders	$ (4,404)	$ (7,987)

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity (Deficit) - USD ($) $ in Thousands	Preferred Stock [Member]	Preferred Stock [Member]Series F Preferred Stock [Member]	Preferred Stock [Member]Series G Preferred Stock [Member]	Common Stock [Member]	Common Stock [Member]Series F Preferred Stock [Member]	Accumulated Deficit [Member]	Accumulated Deficit Attributable to Noncontrolling Interest in Discontinued Operations [Member]	Accumulated Other Comprehensive Loss [Member]	Total	Series F Preferred Stock [Member]	Series G Preferred Stock [Member]
Balance at Dec. 31, 2015	$ 0			$ 262,895		$ (250,738)	$ 0	$ (4,889)	$ 7,268
Balance (in shares) at Dec. 31, 2015		0	0	9,537,415
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock awards under equity incentive plans	0			$ 1,011		0	0	0	1,011
Common stock awards under equity incentive plans (in shares)		0	0	174,825
Issuance of preferred stock and warrants	0			$ (447)		0	0	0	(447)
Dividend on preferred stock - beneficial conversion feature	0			551		(551)	0	0	0
Issuance of common stock to supplier	0			$ 0		0	0	0	0
Issuance of common stock to supplier (in shares)		0	0	950,000
Other	0			$ 222		0	(20)	0	202
Other (in shares)		0	0	128,111
Change in classification of redeemable noncontrolling interest from temporary equity	0			$ 0		0	69	0	69
Proceeds from sale of membership interests	0			0		0	1,740	0	1,740
Foreign currency translation	0			0		0	232	543	775
Net loss	0			0		(8,530)	(2,720)	0	(11,250)
Balance at Dec. 31, 2016	0			$ 264,232		(259,819)	(699)	(4,346)	$ (632)
Balance (in shares) at Dec. 31, 2016		0	0	10,790,351					10,790,351
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock awards under equity incentive plans	0			$ 947		0	0	0	$ 947
Common stock awards under equity incentive plans (in shares)		0	0	642,839
Dividend on preferred stock - beneficial conversion feature	0			$ 778		(778)	0	0	0
Modification of senior debenture holder warrants	0			582		0	0	0	582
Modification of subordinated note holder warrants	0			117		0	0	0	117
Reclassification of preferred stock to equity from temporary equity	1,545			$ 0		0	0	0	1,545
Reclassification of preferred stock to equity from temporary equity (in shares)		3,000	2,000	0
Change in classification of warrants to equity from liability	0			$ 7,980		0	0	0	7,980
Conversion of preferred stock into common stock	(1,232)			$ 1,232		0	0	0	0
Conversion of preferred stock into common stock (in shares)		(3,000)	(1,370)	3,300,118	986,491					499	670
Proceeds from sale of common stock, net of costs	0			$ 2,730		0	0	0	2,730
Proceeds from sale of common stock, net of costs (in shares)		0	0	2,654,732
Exercise of warrant	0			$ 848		0	0	0	848
Exercise of warrant (in shares)		0	0	614,610
Other	0			$ 102		0	0	0	102
Other (in shares)		0	0	44,081
Proceeds from sale of membership interests	0			$ 0		0	650	0	650
Foreign currency translation	0			0		0	56	128	184
Nutra SA divestiture	0			0		0	1,664	4,218	5,882
Net loss	0			0		(4,531)	(1,671)	0	(6,202)
Balance at Dec. 31, 2017	$ 313			$ 279,548		$ (265,128)	$ 0	$ 0	$ 14,733
Balance (in shares) at Dec. 31, 2017		0	630	18,046,731					18,046,731

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flow from operating activities:
Net loss	$ (6,202)	$ (11,250)
Income (loss) from discontinued operations	3,983	(5,120)
Loss from continuing operations	(10,185)	(6,130)
Adjustments to reconcile net loss from continuing operation to net cash used in operating activities of continuing operations:
Depreciation and amortization	757	936
Stock and share-based compensation	1,073	1,275
Change in fair value of derivative warrant and conversion liabilities	(670)	(1,625)
Loss on extinguishment of debt	8,290	0
Gain on resolution of Irgovel purchase litigation	0	(1,598)
Interest accreted	1,000	639
Deferred taxes	(5,046)	(1,869)
Other	32	5
Changes in operating assets and liabilities:
Accounts receivable	(179)	(227)
Inventories	279	808
Accounts payable and accrued expenses	(679)	(201)
Other	303	(467)
Net cash used in operating activities of continuing operations	(5,025)	(8,454)
Net cash provided by operating activities of discontinued operations	1,251	4,519
Net cash used in operating activities	(3,774)	(3,935)
Cash flows from investing activities:
Purchases of property and equipment	(862)	(360)
Net cash used in investing activities of continuing operations	(862)	(360)
Net cash provided by (used in) investing activities of discontinued operations	16,001	(356)
Net cash provided by (used in) investing activities	15,139	(716)
Cash flows from financing activities:
Payments of debt	(19,744)	(32,344)
Proceeds from issuance of debt, net of issuance costs	3,779	30,629
Proceeds from issuance of debt and warrants, net of issuance costs	5,518	300
Proceeds from issuance of preferred stock and warrants, net of issuance costs	1,747	2,554
Proceeds from issuance of common stock, net of issuance costs	2,778	0
Other	(23)	(43)
Net cash provided by (used in) provided by financing activities of continuing operations	(5,945)	1,096
Net cash provided by financing activities of discontinued operations	1,062	907
Net cash provided by (used in) financing activities	(4,883)	2,003
Effect of exchange rate changes on cash and cash equivalents of discontinued operations	154	103
Net change in cash and cash equivalents and restricted cash	6,636	(2,545)
Cash and cash equivalents and restricted cash, beginning of period
Cash and cash equivalents	342	966
Restricted cash	0	1,921
Cash and cash equivalents and restricted cash, beginning of period	342	2,887
Cash and cash equivalents and restricted cash, end of period
Cash and cash equivalents	6,203	342
Restricted cash	775	0
Cash and cash equivalents and restricted cash, end of period	6,978	342
Supplemental disclosures, continuing operations:
Cash paid for interest of continuing operations	811	1,849
Cash paid for income taxes of continuing operations	$ 0	$ 20

LIQUIDITY AND MANAGEMENT'S PLAN

LIQUIDITY AND MANAGEMENT'S PLAN	12 Months Ended
	Dec. 31, 2017
LIQUIDITY AND MANAGEMENT'S PLAN [Abstract]
LIQUIDITY AND MANAGEMENT'S PLAN	NOTE 1. LIQUIDITY AND MANAGEMENT’S PLAN We had reported previously there was substantial doubt about our ability to continue as a going concern. During the fourth quarter of 2017 we substantially completed operational and financial actions, which we believe provides us with sufficient liquidity for the twelve months following the date of this filing. The factors that alleviated the doubt are summarized below: · Cash and cash equivalents and restricted cash increased $6.3 million, from $0.3 million as of December 31, 2016, to $7.0 million as of December 31, 2017. · Operating loss decreased $3.2 million, from $9.3 million in 2016, to $6.1 million in 2017. We can make additional discretionary reductions in operating expenses if necessary. · Our $7.0 million cash position at December 31, 2017 exceeds our $5.0 million negative cash flow from operating activities of continuing operations. We believe our cash flows from operating activities will improve in 2018 because: o We enter 2018 with less than $0.1 million in debt outstanding. Our interest payments are significantly reduced to near zero compared to $0.8 million in 2017 and $1.8 million in 2016. o We enter 2018 having divested of our Healthy Natural (HN) and Nutra SA, LLC (Nutra SA) subsidiaries and refocused on our continuing operations. Nutra SA had been a significant drain on resources. o In 2017, we completed certain operating cost reduction initiatives. In the fourth quarter of 2017 the operating expenses were $2.4 million versus $3.0 million in the 2016 period. We benefited from those cost reduction initiatives for only a portion of 2017 but expect to fully realize the benefit of these reductions beginning in 2018. o We have plans in place to reduce our cost of goods sold and provide additional rice bran supply security. · During 2017, we demonstrated an ability to obtain funds through debt and equity financings at reasonable rates, as discussed further in Note 9. We continue to believe that we will be able to obtain additional funds to operate our business, should it be necessary; however, there can be no assurances that our efforts will prove successful.

BUSINESS

BUSINESS	12 Months Ended
	Dec. 31, 2017
BUSINESS [Abstract]
BUSINESS	NOTE 2 BUSINESS We are an ingredient company serving food, animal nutrition and specialty markets focused on value-added processing and marketing of healthy, natural and nutrient dense products derived from raw rice bran, an underutilized by-product of the rice milling industry. We apply our proprietary and patented technologies and intellectual properties to convert raw rice bran into numerous high value products including stabilized rice bran (SRB), RiBalance, a complete rice bran nutritional package derived from further processing of SRB; RiSolubles, a highly nutritious, carbohydrate and lipid rich fraction of RiBalance; RiFiber, a fiber rich insoluble derivative of RiBalance, and ProRyza, rice bran protein-based products, and a variety of other valuable derivatives extracted from these core products. Our target markets are natural food, food and animal nutrition manufacturers, wholesalers and retailers, both domestically and internationally. We manufacture and distribute SRB, for food and animal nutrition customers, in various granulations along with Stage II products and derivatives. Stage II refers to the proprietary, patented processes run at our Dillon, Montana facility and includes products produced at that facility. Over the past decade, we have developed and optimized our proprietary processes to support the production of healthy, natural, hypoallergenic, gluten free, and non-genetically modified ingredients and supplements for use in meats, baked goods, cereals, coatings, health foods and high-end animal nutrition. We produce SRB inside three locations: two leased raw rice bran stabilization facilities located within supplier-owned rice mills in Arbuckle and West Sacramento, California; and one company-owned rice bran stabilization facility in Mermentau, Louisiana. At our Dillon, Montana facility, we produce our process patented Stage II products including: RiSolubles, a highly nutritious, carbohydrate and lipid rich fraction of SRB; RiFiber, a fiber rich derivative of SRB; RiBalance, a complete rice bran nutritional package derived from further processing SRB, and our ProRyza family of products including, protein- and protein/fiber-based products. We operate proprietary processing equipment and process-patented technology for the stabilization and further processing of rice bran into finished products.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2017
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation Use of Estimates Reclassifications Cash and Cash Equivalents Accounts Receivable and Allowance for Doubtful Accounts Inventories – Property and Equipment We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the undiscounted future cash flows estimated to be generated by the asset to be held and used are not sufficient to recover the unamortized balance of the asset. An impairment loss is recognized based on the difference between the carrying values and estimated fair value. The estimated fair value is determined based on either the discounted future cash flows or other appropriate fair value methods with the amount of any such deficiency charged to operations in the current year. Estimates of future cash flows are based on many factors, including current operating results, expected market trends and competitive influences. Assets to be disposed of by sale are reported at the lower of the carrying amount or fair value, less estimated costs to sell. Revenue Recognition We make provisions for estimated returns, discounts and price adjustments when they are reasonably estimable. Revenues are net of provisions for estimated returns, routine sales discounts, volume allowances and adjustments. Revenues are also net of taxes collected from customers and remitted to governmental authorities. Amounts billed to a customer in a sale transaction for shipping and handling are reported as revenues and the related costs incurred for shipping are included in cost of goods sold. Selling, General and Administrative Expenses Research and Development Share-Based Compensation – For awards of nonvested stock, share-based compensation is measured based on the fair value of the award on the date of grant and the corresponding expense is recognized over the period during which an employee is required to provide service in exchange for the reward. Compensation expense related to service-based awards are recognized on a straight-line basis over the requisite service period for the entire award. For restricted stock units, share-based compensation is measured based on the fair value of the award on the date of grant and the corresponding expense is recognized over the period during which an employee is required to provide service in exchange for the reward. Compensation expense related to service-based awards is recognized on a straight-line basis over the requisite service period for the entire award. We account for share-based compensation awards granted to non-employees and consultants by determining the fair value of the awards granted at either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Generally, we value stock options granted to non-employees and consultants using the Black-Scholes-Merton valuation model and stock at the fair value of the award. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of (i) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached or (ii) the date at which the counterparty’s performance is complete. The expense associated with stock awards issued to consultants or other third parties are recognized over the term of service. In the event services are terminated early or we require no specific future performance, the entire amount is expensed. The value is re-measured each reporting period over the requisite service period. Income Taxes Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards. A valuation allowance is established, when necessary, to reduce that deferred tax asset if it is more likely than not that the related tax benefits will not be realized. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that may be different from current estimates of the tax liabilities. If our estimate of tax liabilities proves to be less than the ultimate assessment, an additional charge to expense would result. If payment of these amounts ultimately proves to be less than the recorded amounts, the reversal of the liabilities may result in income tax benefits being recognized in the period when it is determined that the liabilities are no longer necessary. Recent Accounting Guidance Recent accounting standards not yet adopted The following represent the standards not yet adopted that will, or are expected to, result in a significant change in practice and/or have a significant financial impact on us. In May 2014, the Financial Accounting Standards Board (FASB) issued guidance on revenue from contracts with customers to clarify the principles for recognizing revenue, ASU 2014-09, Revenue: Revenue from Contracts with Customers . In February 2016, the FASB issued guidance which changes the accounting for leases, ASU 2016-02, Leases. Recently adopted accounting standards In November 2016, the FASB issued guidance that requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents, ASU 2016-18, Statement of Cash Flows: Restricted Cash

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	12 Months Ended
	Dec. 31, 2017
DISCONTINUED OPERATIONS [Abstract]
DISCONTINUED OPERATIONS	NOTE 4. DISCONTINUED OPERATIONS Healthy Natural (HN) Discontinued Operations We continuously assess the composition of our business portfolio to ensure it is aligned with our strategic objectives and positioned to maximize growth and return to our shareholders. In the second quarter of 2017, we began exploring strategic options for our wholly-owned subsidiary, HN. On a preliminary basis, we estimate a working capital adjustment of $0.3 million. The working capital adjustment will result in an adjustment to the initial proceeds of $16.7 million and the gain on the sale of $8.2 million, net of a $4.7 million income tax provision. The definition of working capital under the agreement is subject to interpretation and we have not yet finalized the adjustment with the purchaser of HN. The final adjustment may differ from the estimate. The following table summarizes the carrying amount of HN as of the July 14, 2017 sale (in thousands). Accounts receivable, net $ 871 Inventories 1,987 Other current assets 47 Property and equipment 871 Intangible 791 Other 24 Assets 4,591 Accounts payable 759 Accrued expenses 290 Liabilities 1,049 Net assets sold $ 3,542 We determined that the disposal met the criteria for presentation as discontinued operations in the second quarter of 2017. Accordingly, HN results are presented as discontinued operations in our consolidated statements of operations and are excluded from continuing operations for all periods presented. In addition, the HN assets and liabilities are classified as held for sale in our balance sheets for all periods presented. The following table summarizes the carrying amounts of major classes of HN assets and liabilities classified as held for sale (in thousands). December 31, Accounts receivable, net $ 592 Inventories 1,915 Other current assets held for sale 23 Property and equipment 1,019 Intangible 791 Other noncurrent assets 24 Total assets held for sale $ 4,364 Accounts payable $ 443 Accrued expenses 382 Long term liabilities 73 Total liabilities held for sale $ 898 The operations of HN are included in our results though the July 14, 2017 date of sale. The following table summarizes the major line items included in the income (loss) from discontinued operations for HN (in thousands). Years Ended December 31 2017 2016 Revenues $ 9,902 $ 19,678 Cost of goods sold (6,651 ) (13,158 ) Selling, general and administrative expenses (462 ) (1,440 ) Income from operations, before income taxes 2,789 5,080 Income tax expense (1,048 ) (1,864 ) Income from operations, net of tax 1,741 3,216 Gain on sale, net of $4.7 million income tax expense 8,164 - Income from discontinued operations, net of tax $ 9,905 $ 3,216 The following table summarizes the major line items included in cash flows from discontinued operations of HN (in thousands). Years Ended December 31 2017 2016 Net cash provided by operating activities $ 2,403 $ 5,829 Net cash provided by (used in) investing activities 16,693 (99 ) Net cash used in financing activities (52 ) - Net cash provided to continuing operations $ (19,044 ) $ (5,730 ) In 2017, net cash provided by investing activities in the table above is presented in our statements of cash flows in net cash provided by (used in) investing activities of discontinued operations and includes the $16.7 million net proceeds from the sale of HN. The following table summarizes other data for HN (in thousands). Years Ended December 31 2017 2016 Depreciation included in cost of goods sold $ 96 $ 175 Depreciation included in selling, general and administrative expenses 49 72 Amortization included in selling, gneral and administrative expenses - 863 Capital expenditures 18 100 Nutra SA Discontinued Operations We held a variable interest in our equity interest in Nutra SA. Nutra SA’s only operating subsidiary is Industria Riograndens De Oleos Vegetais Ltda. (Irgovel), located in Pelotas, Brazil. On November 28, 2017 Nutra SA redeemed our entire membership interest in Nutra SA and we paid Nutra SA $0.5 million in concurrent transactions. We no longer hold any interest in Nutra SA. We were the primary beneficiary of Nutra SA, and as such, Nutra SA’s assets, liabilities and results of operations are included in the consolidated financial statements through November 28, 2017, the date of disposal of Nutra SA. In the second quarter of 2017, we determined that our plans to divest our investment in Nutra SA met the criteria for presentation as discontinued operations. Accordingly, the Nutra SA operating results are presented as discontinued operations and are excluded from continuing operations for all periods presented. In addition, Nutra SA consolidated assets and liabilities are classified as held for sale in our consolidated balance sheets for all periods presented. Other equity holders’ (Investors) interests in Nutra SA are reflected in net loss attributable to noncontrolling interest in discontinued operations in the consolidated statements of operations and accumulated deficit attributable to noncontrolling interest in discontinued operations in the consolidated balance sheets. The Investors average interest in Nutra SA was 36% in 2017, through the date of disposal, and 32% in 2016. We use the U.S. Dollar as our reporting currency. The functional currency for Irgovel was the Brazilian Real. Assets and liabilities of Irgovel classified as held for sale were translated using the exchange rate in effect at December 31, 2016, and at the date of disposal, November 28, 2017, when determining the loss on disposal. Equity accounts were translated at historical rates, except for the change in accumulated deficit during the year, which is the result of the income statement translation process. Irgovel’s revenues and expenses were translated using the average exchange rates in effect during the period. Translation differences were recorded in accumulated other comprehensive income (loss) as foreign currency translation. Gains or losses on transactions denominated in a currency other than Irgovel’s functional currency which arose as a result of changes in foreign exchange rates were recorded as foreign exchange gain or loss in net income (loss). We recorded a $1.2 million loss on disposal of Nutra SA in the fourth quarter of 2017. The following table summarizes the estimated carrying amount of the Nutra SA net liabilities disposed as of the November 28, 2017, disposal date and the components of the Nutra SA loss on disposal (in thousands). Cash $ 20 Accounts receivable, net 653 Inventories 630 Other current assets 413 Property and equipment 10,070 Other 1,435 Accounts payable (2,560 ) Accrued expenses (7,878 ) Debt (7,345 ) Net liabilities disposed (4,562 ) Foreign curency translation adjustment 4,218 Redeemable noncontrolling interest 1,663 Payments to purchaser at disposal 540 Other 37 Loss on disposal of Nutra SA 1,896 Income tax benefit (694 ) Loss on disposal of Nutra SA, net of tax $ 1,202 The following table summarizes the carrying amounts of major classes of Nutra SA assets and liabilities classified as held for sale as of December 31, 2016 (in thousands). December 31, Cash and cash equivalents $ 109 Accounts receivable, net (restricted) 398 Inventories 925 Other current asssets 373 Property and equipment, net (restricted $2,662) 10,889 Other noncurrent assets 1,327 Total assets held for sale $ 14,021 Accounts payable $ 2,553 Accrued expenses 5,607 Current maturities of long-term debt (nonrecourse) 6,816 Total liabilities held for sale $ 14,976 Cash provided by Nutra SA operations was generally unavailable for distribution to our continuing operations under to the terms of the LLC Agreement. Therefor Nutra SA’s consolidated cash is classified as held for sale in our consolidated balance sheets. Nutra SA’s debt was secured by Irgovel’s accounts receivable and property. The non-Brazilian entities within the consolidated ownership group did not guarantee any of Nutra SA’s debt. No interest related to debt held by non-Brazilian entities was allocated to Nutra SA in any period presented. The following table summarizes the major line items included in income (loss) from discontinued operations for Nutra SA (in thousands). Years Ended December 31 2017 2016 Revenues $ 12,209 $ 6,744 Cost of goods sold (12,517 ) (8,423 ) Selling, general and administrative expenses (3,188 ) (2,255 ) Goodwill impairment - (3,024 ) Other expense (1,224 ) (1,378 ) Loss from discontinued operations, before income taxes (4,720 ) (8,336 ) Income taxes - - Loss from operations, net of tax (4,720 ) (8,336 ) Loss on dispoal, net of $0.7 million taxes (1,202 ) - Loss form discontinud operations, ne tof tax $ (5,922 ) $ (8,336 ) The following table summarizes the major line items included in cash flows from Nutra SA (in thousands). Years Ended December 31 2017 2016 Net cash used in operating activities $ (1,152 ) $ (1,310 ) Net cash used in investing activities (692 ) (257 ) Net cash provided by financing activities 1,114 907 Effect of exchange rate changes 154 103 Net cash provided by continuing operations $ (576 ) $ (557 ) In 2017, net cash used in investing activities in the table above is presented in our consolidated statements of cash flows in net cash provided by (used in) investing activities of discontinued operations and includes the $0.5 million net payments upon divestiture of Nutra SA. The following table summarizes other data for Nutra SA (in thousands). Years Ended December 31 2017 2016 Depreciation included in cost of goods sold $ 897 $ 932 Depreciation included in selling, general and administrative expenses 56 57 Capital expenditures 142 257

INCOME (LOSS) PER SHARE (EPS)

INCOME (LOSS) PER SHARE (EPS)	12 Months Ended
	Dec. 31, 2017
INCOME (LOSS) PER SHARE (EPS) [Abstract]
INCOME (LOSS) PER SHARE (EPS)	NOTE 5. INCOME (LOSS) PER SHARE (EPS) Basic EPS is calculated under the two-class method under which all earnings (distributed and undistributed) are allocated to each class of common stock and participating securities based on their respective rights to receive dividends. Our outstanding convertible preferred stocks are considered participating securities as the holders may participate in undistributed earnings with holders of common shares and are not obligated to share in our net losses. Diluted EPS is computed by dividing the net income attributable to RiceBran Technologies common shareholders by the weighted average number of common shares outstanding during the period increased by the number of additional common shares that would have been outstanding if the impact of assumed exercises and conversions is dilutive. The dilutive effects of outstanding options, warrants, nonvested shares and restricted stock units that vest solely on the basis of a service condition are calculated using the treasury stock method. The dilutive effects of the outstanding preferred stock are calculated using the if-converted method. Below are reconciliations of the numerators and denominators in the EPS computations. Years Ended December 31 2017 2016 NUMERATOR (in thousands): Basic and diluted - loss from continuing operations $ (10,185 ) $ (6,130 ) Dividend on preferred stock--beneficial conversion feature (778 ) (551 ) Basic and diluted - adjusted loss from continuing operations $ (10,963 ) $ (6,681 ) DENOMINATOR (in thousands): Basic EPS - weighted average number of common shares outstanding 11,923,923 9,338,370 Effect of dilutive securities outstanding - - Diluted EPS - weighted average number of shares outstanding 11,923,923 9,338,370 Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive: Stock options 514,961 305,355 Warrants 21,588,045 10,308,778 Convertible preferred stock 2,529,872 1,708,791 Restricted stock units 601,986 - Weighted average number of nonvested share of common stock not included in diluted EPS because effect would be antidilutive 1,249,234 1,132,724 The impacts of potentially dilutive securities outstanding at December 31, 2017 and 2016, were not included in the calculation of diluted EPS in 2017 and 2016 because to do so would be anti-dilutive. Those securities listed in the table above which were anti-dilutive in 2017 and 2016, which remain outstanding, could potentially dilute EPS in the future.

CONCENTRATION OF RISK

CONCENTRATION OF RISK	12 Months Ended
	Dec. 31, 2017
CONCENTRATIONS OF RISK [Abstract]
CONCENTRATIONS OF RISK	NOTE 6. CONCENTRATION OF RISK Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of trade accounts receivable. We perform ongoing credit evaluations on the financial condition of our customers and generally do not require collateral. Revenues and accounts receivable from significant customers (customers with revenue or accounts receivable in excess of 10% of consolidated totals) are stated below as a percent of consolidated totals. Customer A B C % of revenue, 2017 17% 14% 8% % of revenue, 2016 14% 15% 12% % of accounts receivable, as of December 31, 2017 25% 0% 7% % of accounts receivable, as of December 31, 2016 28% 0% 7% We purchase rice bran from four suppliers. Purchases from these suppliers represent 37% of our cost of goods sold in 2017 and 33% of our cost of goods sold in 2016. The following table presents revenues by geographic area shipped to (in thousands). Years Ended December 31 2017 2016 United States $ 12,196 $ 11,806 Other international 1,159 1,176 Revenues $ 13,355 $ 12,982 T Years Ended December 31 2017 2016 Food $ 7,525 $ 7,643 Animal nutrition 5,830 5,339 Revenues $ 13,355 $ 12,982

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2017
PROPERTY AND EQUIPMENT [Abstract]
PROPERTY AND EQUIPMENT	NOTE 7. PROPERTY AND EQUIPMENT December 31 2017 2016 Estimated Useful Lives Land $ 237 $ 237 Furniture and fixtures 311 306 5-7 years Plant 6,580 6,582 30 years, or life of lease Computer and software 1,207 1,147 3-5 years Leasehold improvements 274 261 4-7 years or life of lease Machinery and equipment 8,677 7,274 5-10 years Property and equipment, cost 17,286 15,807 Less accumulated depreciation 9,436 8,782 Property and equipment, net $ 7,850 $ 7,025 Depreciation expense was $0.6 million in 2017 and $0.8 million and 2016.

DEBT

DEBT	12 Months Ended
	Dec. 31, 2017
DEBT [Abstract]
DEBT	NOTE 8. DEBT The following table summarizes current and long-term portions of debt as of December 31, 2017 and 2016 (in thousands): 2017 2016 Senior revolving loan $ - $ 1,725 Senior term loan, net - 917 Subordinated notes - 6,310 Other 16 75 16 9,027 Current portion 4 3,063 Long-term portion $ 12 $ 5,964 We issued senior debentures in the principal amount of $6.6 million and related warrants in a private placement, in February 2017 . The transactions, and the accounting therefore, are Until July 2017, when we repaid the senior debentures and the subordinated notes in full with the proceeds from the sale of HN in July 2017, w . Upon extinguishment in July 2017, we recognized a loss on extinguishment of $6.6 million for the differences between (i) the $0.6 million carrying amount of the senior debentures and the $6.6 million face value paid and (ii) the $5.3 million carrying amount of the subordinated notes and the $6.0 million face value paid. In February 2017, we used the net proceeds from the senior debenture private placement, discussed further in Note 9, to pay the senior revolving loan and the senior term loan in full.

EQUITY, SHARE-BASED COMPENSATIO

EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONS	12 Months Ended
	Dec. 31, 2017
EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONS [Abstract]
EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONS	NOTE 9. EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONSS In February 2017, shareholders approved and we filed an amendment to our articles of incorporation increasing our authorized shares of common stock from 25,000,000 to 50,000,000. Our board of directors, without further action or vote by holders of our common stock, has the right to establish the terms, preference, rights and restrictions and issue shares of preferred stock. We previously designated and issued six series of preferred stock of which no shares remain outstanding. In addition, we have designated and issued a seventh series of preferred stock: 2,000 shares of Series G in 2017, of which 630 shares remain outstanding. The Series G preferred stock is non-voting and may be converted into shares of our common stock at the holders’ election at any time, subject to certain beneficial ownership limitations, at a ratio of 1 preferred share for 948.9915 shares of common stock. The Series G preferred stock is entitled to receive dividends if we pay dividends on our common stock, in which case the holders of Series G preferred stock are entitled to receive the amount and form of dividends that they would have received if they held the common stock that is issuable upon conversion of the Series G preferred stock. If we are liquidated or dissolved, the holders of Series G preferred stock are entitled to receive, before any amounts are paid in respect of our common stock, an amount per share of Series G preferred stock equal to $1,000, plus any accrued but unpaid dividends thereon. Series F preferred stock is no longer outstanding. The Series F preferred stock was non-voting and could be converted into shares of our common stock at the holder’s election at any time, subject to certain beneficial ownership limitations, at a ratio of 1 preferred share for 666.66666 shares of common stock. The Series F preferred stock was only entitled to receive dividends if we declared dividends, in which case the dividend was to be paid (i) first an amount equal to $0.01 per share of preferred stock and (ii) then to and in the same form as dividends paid on shares of our common stock. Otherwise, the Series F preferred stock had no liquidation or other preferences over our common stock. Share-based compensation expenses related to stock options, stock and restricted stock units issued to employees and directors are included in selling, general and administrative expenses. The following table provides a detail of share-based compensation expense (in thousands). Years Ended December 31 2017 2016 Stock options $ 176 $ 243 Common stock, vested at issuance and nonvested at issuance 744 768 Restricted stock units 27 - Compensation expense related to common stock awards issued under equity incentive plans $ 947 $ 1,011 Share Sequencing From June 2015 until March 2017, the minority interest holders in Nutra SA could elect , the number of common stock and warrants issuable upon this election, was variable and indeterminate. For accounting purposes, we were not able to conclude that we had sufficient authorized and unissued shares to settle all contracts subject to the GAAP derivative guidance during the period the minority interest holders had this right, which right terminated March 31, 2017. Our adopted sequencing approach (Share Sequencing) was based on earliest issuance date, therefore, we were required to carry warrants issued between June 2015 and March 2017, at fair value, as derivative warrant liability, and preferred stock issued between June 2015 and March 2017, Warrants The following table summarizes information related to outstanding warrants: December 31, 2017 December 31, 2016 Range of Exercise Prices Type of Warrant Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Under Warrants, Exercisable Cashless Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) (4 ) $ 0.96 Equity 12,972,832 0.96 4.1 3,774,344 - - - $ 1.50 to $1.60 Liability (1)(3) - - - - 1,789,868 1.52 1.3 $ 1.60 Equity (1) 300,000 1.60 2.4 300,000 - - - $ 2.00 Liability (2) - - - - 2,660,000 2.00 4.6 $ 2.00 Equity 2,660,000 2.00 3.6 - - - - $ 5.25 Liability (2) - - - - 25,000 5.25 3.6 $ 5.25 to $5.87 Equity 3,156,670 5.33 1.7 359,536 4,296,339 5.36 2.7 $ 6.55 to $16.80 Equity 2,067,771 6.61 1.0 190,899 2,067,771 6.61 2.0 21,157,273 $ 2.30 3.4 4,624,779 10,838,978 $ 4.14 2.8 (1) Includes a warrant for the purchase of up to purchase 300,000 shares of common stock which contains a most favored nations anti-dilution provision. Under that provision, in the event we issue warrants and/or other convertible instruments with anti-dilution provisions with respect to the exercise price of the warrant or the conversion price of the convertible instrument, we will be required to provide the same anti-dilution provision in this warrant and may be required to lower the exercise price on this warrant and/or increase the number of shares underlying this warrant. The warrant also contains a provision in effect until November 2017 which gave the holder the right to demand a net cash settlement in the event of a fundamental transaction (as defined in the agreement). The warrant was classified as derivative warrant liability in our balance sheets due to that provision as of December 31, 2016, and was reclassified to equity (deficit) in November 2017 when the provision expired. (2) The warrants were classified as derivative warrant liabilities in our balance sheets due to the Share Sequencing as of December 31, 2016, and were reclassified to equity (deficit) effective March 31, 2017. (3) Includes warrants for the purchase 1,489,868 shares of common stock, at December 31, 2016, which contained full ratchet anti-dilution provisions. The warrants were classified as derivative warrant liability in our balance sheets due to that provision as of December 31, 2016, and were exercised in 2017. (4) Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature. The shares listed, represent the shares holders could exercise cashless as of December 31, 2017. If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise. Should we fail to maintain a registration statement for the resale of shares under certain other warrant, the shares under those warrants may be exercisable using a cashless exercise feature. The following table summarizes warrant activity. Equity Warrants Liability Warrants Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding, December 31, 2015 6,367,139 $ 4.02 2.8 726,489 $ 5.24 2.9 Issued - NA NA 2,685,000 2.03 5.0 Impact of repricing senior lender warrants: Prior to repricing - NA NA (300,000 ) 5.25 3.9 After repricing - NA NA 300,000 1.80 3.9 Prior to repricing - NA NA (300,000 ) 1.80 3.7 After repricing - NA NA 300,000 1.60 3.7 Impact of anti-dilution clauses: Prior to impact - NA NA (426,489 ) 5.24 1.8 After impact - NA NA 1,489,868 1.50 1.8 Exercised - NA NA - NA NA Forfeited, expired or cancelled (3,029 ) 46.80 - - NA NA Outstanding, December 31, 2016 6,364,110 5.77 2.44 4,474,868 1.82 3.3 Issued 25,000 0.96 5.01 11,783,163 0.96 5.0 Impact of repricing senior debenture purchaser warrants: Prior to repricing (875,000 ) 5.49 2.1 - NA NA After repricing 875,000 0.96 5.5 - NA NA Impact of repricing subordinated note holder warants: Prior to repricing (289,669 ) 5.25 3.3 - NA NA After repricing 289,669 0.96 3.3 - NA NA Impact of anti-dilution clauses: Prior to impact - NA NA (1,489,868 ) 1.50 0.8 After impact - NA NA 2,327,919 0.96 0.8 Transfer from liability to equity 14,768,163 1.16 4.8 (14,768,163 ) 1.16 4.8 Exercised - NA NA (2,327,919 ) 0.96 - Forfeited, expired or cancelled - NA NA - NA NA Outstanding, December 31, 2017 21,157,273 $ 2.30 3.4 - $ - - Exercisable, December 31, 2017 21,157,273 $ 2.30 3.4 - $ - - In the period from January 1, 2018 to March 8, 2018, we issued warrants for the purchase of up to 315,000 shares of common stock, at a weighted average exercise price of $4.73 per share and a weighted average term of 2.4 years. We recognized $0.1 million of expense for these issuances. During the same period, warrant holders exercised, at $0.96 per share, warrants for the purchase of 67,395 shares of common stock (remaining term at December 31, 2017 of 4.1 years). Transactions with Preferred Stock Holders. In February 2017, we issued and sold 2,000 shares of Series G preferred stock and sold warrants to purchase 1,423,488 shares of common stock (exercise price of $0.96 per share, exercisable beginning in February 2017 and expiring in February 2022). A subordinated note holder exchanged subordinated notes with a principal and carrying value of $0.1 million and cash for 180 shares of the Series G preferred stock and related warrants, which was treated as an extinguishment of debt. The net cash proceeds from the sale was $1.7 million, after deducting allocated cash offering expenses of $0.1 million. On the date of issuance, we allocated $1.0 million of the proceeds to derivative warrant liability, to record the warrants at fair value, recorded a $0.1 million loss on extinguishment and reduced debt $0.1 million related to the subordinated noteholders exchange, and recorded $1.2 million as preferred stock. We recorded a $0.8 million dividend on preferred stock for the preferred stock beneficial conversion feature equal to the proceeds allocated to the preferred stock issued to purchases who did not exchange debt, as the fair value of the common stock underlying the convertible preferred stock at issuance exceeded the amount recorded in preferred stock. In February 2016, we issued and sold 3,000 shares of Series F preferred stock and sold warrants to purchase 2,660,000 shares of common stock (exercise price of $2.00 per share, exercisable beginning in August 2016 and expiring in August 2021). The placement agent for the offering received a cash fee of $0.2 million. The net proceeds from the offering were $2.6 million, after deducting cash offering expenses of $0.4 million. On the date of issuance, we allocated $2.5 million of the $3.0 million gross proceeds to derivative warrant liability, to record the warrants at fair value and recorded the remaining $0.5 million proceeds as preferred stock. We recorded a dividend on preferred stock for the preferred stock beneficial conversion feature equal to the proceeds allocated to the preferred stock at issuance ($0.5 million), as the fair value of the common stock underlying the convertible preferred stock at issuance was $2.7 million. As a result of this offering, the exercise price of certain warrants that contained full ratchet anti-dilution provisions was reduced from $5.24 per share to $1.50 per share and the number of shares of common stock underlying these warrants increased from 426,489 shares to 1,489,868 shares. Transactions with Senior Debenture Holders In February 2017, we sold and issued in a private placement, for an aggregate subscription amount of $6.0 million: (i) senior debentures in the principal amount of $6.6 million and (ii) warrants to purchase an aggregate of 6,875,000 shares of common stock (exercise price of $0.96 per share, exercisable beginning February 2017 and expiration February 2022). We received aggregate net proceeds of $5.5 million, after deducting placement agent fees and allocated expenses of $0.5 million. Concurrently, we amended existing warrants, held by the debenture purchasers, for the purchase of up to 875,000 shares to (i) reduce the exercise prices from an average $5.49 per share to $0.96 per share, providing the warrants are not exercisable until August 2017, and (ii) change the expiration dates to August 2022, which increased the average remaining term of the warrants from 2.1 years to 5.5 years. We recorded $4.6 million as an increase to derivative warrant liabilities, to record the warrants at their fair value on the date of issuance, the $0.5 million as an increase in common stock to record the change in fair value of existing warrants and the remaining $0.4 million to debt, debt issuance costs and debt discount. We used the net proceeds from the offering to (i) pay off the senior revolving loan and term loan debt totaling $3.8 million and (ii) pay $0.2 million of principal and $0.3 million of interest due on subordinated notes and (iii) for working capital and general corporate purposes. We filed a registration statement on Form S-3, which became effective in May 2017, to register the shares under the warrants issued to the senior debenture purchasers. Transaction with Subordinated Note Holders In connection with the February 2017 senior debenture private placement, we entered into agreements which resulted in (i) a reduction in the annual interest rate on the subordinated notes from 11.75% to 7% (ii) an extension of the maturity date of the subordinated notes to May 2019 from May 2018 (iii) the payment of an aggregate amount equal to $0.5 million on the subordinated notes; (iv) the issuance of warrants to purchase up to 3,484,675 shares of our common stock (exercise price of $0.96 per share, expiration February 2022); and (v) the amendment of existing warrants held by the subordinated note holders for the purchase 289,669 shares of common stock to reduce the exercise price from $5.25 per share to $0.96 per share. We accounted for the transaction as an extinguishment of debt and issuance of new debt. In February 2017, we (i) recorded a loss on extinguishment of debt of $1.5 million, (ii) adjusted subordinated notes payable debt down by $0.9 million, to its fair value as of the transaction date, (iii) increased derivative liability by $2.3 million, representing the fair value of the newly issued warrants, and (iv) increased common stock equity by $0.1 million for the change in the fair value of the existing warrants. Transaction with Senior Lender In June 2016, we amended an agreement with a senior lender to extend the terms of a loan agreement and repriced a previously issued warrant held by the lender from an exercise price per share of $5.25 to $1.85. In September 2016, we amended the terms of the loan agreement with the lender to further extend the terms of the loan agreement and repriced the warrant held by the lender from an exercise price per share of $1.85 to $1.60. Both prior to and subsequent to these modifications, we recorded the warrant at fair value as a derivative warrant liability, pursuant to the Share Sequencing, with changes in fair value recorded in net income (loss). Transactions with Other Note Holders In January 2016, we entered into a note payable with a director in the principal amount of $0.3 million and issued the director a warrant to acquire 25,000 shares of common stock (exercise price of $5.25 per share, exercisable immediately and expiring in January 2021). On the date of issuance, we recorded the warrant at fair value as a derivative warrant liability, pursuant to the Share Sequencing, and recorded a corresponding debt discount which amortized to interest expense when we repaid the note and accumulated interest in full in March 2016. Transactions with Holders of Warrants with Full Ratchet Anti-Dilution Clauses As a result of the February 2017 financing transactions described above, the exercise price of certain warrants that contained full ratchet anti-dilution provisions was reduced from $1.50 per share to $0.96 per share and the number of shares of common stock underlying these warrants increased from 1,489,868 shares to 2,327,919 shares. The holder of the warrants subsequently exercised the warrants and we issued 614,610 shares of common stock to the holder, with a weighted average fair value on the dates of conversion of $1.38 per share, in a cashless transaction and recorded a $0.1 million loss on the conversion equal to the difference between the fair value of the liabilities and the fair values of the common stock on the dates of the conversion. Other Equity Issuances In February 2016, we issued 950,000 shares of common stock to a supplier. The shares are being held in escrow until earned (as defined in our agreement) by the supplier at a fixed price of $2.80 per share. Cumulatively, as of December 31, 2017, 59,292 shares have been released from escrow. We may recall any shares remaining in escrow as of February 8, 2026. Any recalled shares will be cancelled. In February 2017, we issued a former employee 108,696 shares of our common stock, in lieu of paying $100,000 cash for a 2016 bonus. In June 2017, we issued 96,372 shares of common stock as transitional director compensation to the chairman of our board, who was awarded transitional director compensation in the amount of (i) $10,000 or 7,035 shares per month for July 2016 through December 2016 and (ii) $8,333 or 9,027 shares per month for January 2017 through March 2017. The amount was payable in either cash or stock at the chairman’s election. The chairman elected to receive shares of common stock. In June 2017, we issued 345,205 shares of common stock to our directors at a grant date fair value of $0.90 per share. In August 2017, we issued 35,336 shares of common stock to a director at a grant date fair value of $1.09 per share. The stock awards vest on the earlier of June 2018 or one day before the date of the next annual shareholder meeting. In September 2017, we issued and sold 2,654,732 shares of common stock for $1.08 per share. The net proceeds from the offering of $2.8 million, after deducting commissions and other cash offering expenses of $0.1 million, are included in common stock. We used the proceeds for general corporate purposes. In 2017, we issued 986,491 shares of common stock upon conversion of 499 shares of Series F preferred stock and 670 shares of Series G preferred stock. We reclassified the $0.4 million carrying value of the related preferred stock to common stock. In January 2018, we issued 50,469 shares of common stock to employees and 14,129 shares of common stock to a consultant, with a fair value at issuance of $1.38 per share. Equity Incentive Plan Our board of directors adopted our 2014 Equity Incentive Plan (2014 Plan) in August 2014, after the plan was approved by shareholders. A total of 1,600,000 shares of common stock were initially reserved for issuance under the plan. In June 2017, shareholders approved a 1,700,000 increase in the authorized shares issuable under the 2014 Plan. The total shares authorized under the plan is now 3,300,000 shares. Options A summary of stock option activity follows. Shares Under Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding, December 31, 2015 357,797 $ 12.12 7.9 Granted - NA NA Exercised - NA NA Forfeited, expired or cancelled (186,986 ) 8.88 6.5 Outstanding, December 31, 2016 170,811 8.83 7.2 Granted 481,500 0.79 10.0 Exercised - NA NA Forfeited, expired or cancelled (12,652 ) 3.62 8.1 Outstanding, December 31, 2017 639,659 $ 2.91 8.5 As of December 31, 2017, outstanding stock options had an intrinsic value of $0.3 million, the weighted average remaining vesting period of options outstanding was 3.8 years and unrecognized option compensation cost was $0.2 million. The average fair value of stock options granted was $2.68 per share in 2017. The following are the assumptions used in valuing the 2017 stock option grants: Year Ended December 31, 2017 Assumed volatility 85% - 87% (87% weighted average) Assumed risk free interest rate 1.8% - 2.0% (2.0% weighted average) Average expected life of options (in years) 6.2 (6.2 weighted average) Expected dividends - The following table summarizes information related to outstanding and exercisable stock options as of December 31, 2017: Outstanding Exercisable Range of Exercise Prices Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) $ 0.76 to $0.91 450,500 $ 0.83 9.3 53,332 $ 0.79 9.2 $ 1.09 to $1.98 31,000 1.27 9.4 5,000 1.98 7.9 $ 2.91 to $2.97 19,000 2.97 7.6 14,828 2.97 7.6 $ 3.47 34,790 3.47 7.5 32,429 3.47 7.5 $ 4.27 to $6.00 55,243 4.63 6.6 55,147 4.83 6.6 $ 16.00 42,335 16.00 3.9 42,335 16.00 3.9 $ 28.00 to $74.00 6,791 49.94 3.6 6,791 49.94 3.6 639,659 $ 2.91 8.5 209,862 $ 7.06 6.8 In January 2018, we issued options to employees for the purchase of up to 278,873 shares of common stock at an exercise price of $1.42 and a grant date fair value of $0.97 per share. The options vest and become exercisable in four equal annual installments beginning in January 2019. Restricted Stock Units In late June 2017, we issued restricted stock units (RSUs), under the 2014 Plan, to our executive officers covering a total of 1,175,000 shares of our common stock. The shares subject to the RSUs vest based upon a vesting price equal to the volume weighted average trading price of our common stock over sixty-five consecutive trading days. Each RSU’s shares vest (i) 10% if the vesting price equals or exceeds $5.00 per share, (ii) 30% if the vesting price equals or exceeds $10.00 per share and (iv) 60% if the vesting price equals or exceeds $15.00 per share. The shares had a grant date fair value of $0.2 million which was being expensed ratably over a 3.5-year period beginning in July 2017. In January 2018, 60% of the RSUs issued in June 2017 were cancelled. The portion cancelled related to the $15.00 per share target vesting price. Nonvested Stock Shares Issued to Employees and Directors Weighted Average Grant Date Fair Value Fair Value (in thousands) Weighted Average Remaining Vesting (Years) Unrecognized Stock Compensation (in thousands) (a) Nonvested at December 31, 2015 324,229 $ 4.25 $ 616.0 1.66 $ 796.3 Granted 174,825 1.46 255.00 Vested (242,215 ) (b) 4.16 323.00 Forfeited - NA NA Nonvested at December 31, 2016 256,839 2.44 265.00 0.7 284.6 Granted 380,541 0.92 349.00 Vested (252,636 ) (c) 2.42 220.00 Forfeited - NA NA Nonvested at December 31, 2017 384,744 (d) $ 0.94 $ 569.0 0.5 $ 176.3 (a) Represents pre-tax fair value, based on our closing stock prices, which would have been received by the holders of the stock had all such holders sold their underlying shares on the date indicated, the dates of grant or the dates of vesting, as applicable. (b) Includes 147,836 shares, for which vesting was accelerated in November 2016, based on the terms of a severance agreement. (c) Includes 73,608 shares, for which vesting was accelerated in June 2017, based on the terms of a severance agreement. (d) Excludes 890,708 shares, issued to a supplier, nonvested and unearned as of December 31, 2017. The shares are being held in escrow until earned (as defined in our agreement) by the supplier at a fixed price of $2.80 per share

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2017
INCOME TAXES [Abstract]
INCOME TAXES	NOTE 10. INCOME TAXES On December 22, 2017, the United States enacted significant changes to U.S. tax law following the passage and signing of H.R.1, “An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal Year 2018” (the Tax Act). The Tax Act reduces the U.S. federal corporate tax rate to a maximum of 21 percent. As of December 31, 2017, we have not completed our accounting for the tax effects of the enactment of the Tax Act, however, in certain cases, as described below, we have made a reasonable estimate of the effects on our existing deferred tax balances. The application of this rate reduction to the ending deferred tax assets and deferred tax liabilities impacted our expense for income taxes by $7.1 million which was fully offset by a corresponding change to our valuation allowance in 2017. We are still analyzing the Tax Act and refining our calculations, which could potentially impact the measurement of our tax balances. The Tax Act contains several base broadening provisions that became effective on January 1, 2018, that we do not expect to have a material impact on future earnings. The 2017 impact of the enactment of the Tax Act is reflected in the tables below. Deferred tax asset (liability) is comprised of the following (in thousands): December 31 2017 2016 Net operating loss carryforwards $ 5,560 $ 7,946 Capital loss 7,030 363 Stock options and warrants 322 724 Property 499 743 Intangible assets 89 (252 ) Capitalized expenses 142 342 Debt and deferred financing - 178 Other 230 466 Net deferred tax assets 13,872 10,510 Less: Valuation allowance (13,872 ) (10,510 ) Deferred tax asset (liability) $ - $ - Deferred taxes arise from temporary differences in the recognition of certain expenses for tax and financial reporting purposes. We have determined it is more likely than not that some portion or all of the deferred tax assets will not be realized. Accordingly, we have provided a valuation allowance for deferred tax assets. The following table summarizes the change in the valuation allowance (in thousands). Years Ended December 31 2017 2016 Vaulation allowances at beginning of year $ 10,510 $ 5,726 Net operating loss 4,358 5,021 Expiration of net operating losses and limitations 2,353 (105 ) Effect of federal rate reduction from 34% to 21% (7,079 ) - Capital loss from redemption of Nutra SA interests 11,058 - Other adjusments (1,384 ) (132 ) Change in valuation allowance, before transfer 9,306 4,784 Transferred from discontinued operations (5,944 ) - Valuation allowances at end of year $ 13,872 $ 10,510 As of December 31, 2017, net operating loss carryforwards for U.S. federal tax purposes totaled $22.5million and expire at various dates from 2021 through 2037. Net operating loss carryforwards for state tax purposes totaled $15.6 million at December 31, 2017, and expire at various dates from 2018 through 2037. We generated a capital loss carryforward of $29.1 million from the redemption of membership interest in Nutra S.A. for which the Company does not expect to realize benefit. Therefore, a valuation allowance has been recorded as of December 31, 2017. We experienced several ownership changes as defined in IRC Section 382(g) as a result of offerings and conversions that occurred in 2013 and 2014 and a new shareholder obtaining a greater than 5% interest in the value our equity in September 2017. Our ability to utilize previously accumulated net operating loss carryforwards was subject to substantial annual limitations due to change in ownership provisions of the Internal Revenue Code of 1986, as amended, and similar state regulations. In the fourth quarter of 2017 we completed a formal analysis to determine the amount of annual limitation on net operations loss carryforwards prior to utilization. We are subject to taxation in the U.S. federal jurisdiction and various state and local jurisdictions. We record liabilities for income tax contingencies based on our best estimate of the underlying exposures. We are open for audit by the IRS for years after 2013 and, generally, by U.S. state tax jurisdictions after 2012. Because we had a net loss from continuing operations and net income from discontinued operations, we were required to allocate a tax benefit to net loss from continuing operations under financial accounting guidance (ASC 740-25-7) in both 2017 and 2016. The tax benefit allocated to the loss from continuing operations was limited to the lesser of the tax effect of the loss from continuing operations or the tax avoided on the overall net pretax income from discontinued operations that provide a source of realization of the continuing operations loss. The components of income tax benefit follow (in thousands). Years Ended December 31 2017 2016 Current: State $ 16 $ 45 Deferred: Federal (4,684 ) (1,732 ) State (362 ) (137 ) Total deferred (5,046 ) (1,869 ) Income tax benefit $ (5,030 ) $ (1,824 ) Reconciliations between the amount computed by applying the U.S. federal statutory tax rate (34%) to loss before income taxes, and income tax benefit follows (in thousands): Years Ended December 31 2017 2016 Income tax benefit at federal statutory rate $ (5,173 ) $ (2,704 ) Increase (decrease) resulting from: State tax benefit, net of federal tax effect (400 ) (214 ) Effect of federal rate reduction from 34% to 21% 7,079 - Change in valuation allowance 9,306 4,784 Capital loss from redemption of Nutra SA interests (11,058 ) - Expiration of net operating losses (310 ) 105 Reduction in deferred balances for forfeited, expired or cancelled options 317 168 Nontaxable fair value adjustment (234 ) (553 ) Nondeductible expenses 55 (465 ) Other adjustments to deferred balances - (994 ) Allocated from discontinud operations (5,046 ) (1,864 ) Other 434 (86 ) Income tax benefit $ (5,030 ) $ (1,824 ) We recognize interest and penalties related to uncertain tax positions in selling, general and administrative expenses. We have not identified any uncertain tax positions requiring a reserve as of December 31, 2017 or 2016. We do not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months .

FAIR VALUE MEASUREMENT

FAIR VALUE MEASUREMENT	12 Months Ended
	Dec. 31, 2017
FAIR VALUE MEASUREMENT [Abstract]
FAIR VALUE MEASUREMENT	NOTE 11. FAIR VALUE MEASUREMENT The fair value of cash and cash equivalents, restricted cash, accounts and other receivables and accounts payable approximates their carrying value due to shorter maturities. As of December 31, 2017, the fair value of our debt (Level 3 measurement) approximated its carrying value, based on current market rates for similar debt with similar maturities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Certain assets and liabilities are presented in the financial statements at fair value. Assets and liabilities measured at fair value on a recurring basis include derivative warran t We assess the inputs used to measure fair value using a three-tier hierarchy based on the extent to which inputs used in measuring fair value are observable in the market: ● Level 1 – inputs include quoted prices for identical instruments and are the most observable. ● Level 2 – inputs include quoted prices for similar assets and observable inputs such as interest rates, currency exchange rates and yield curves. ● Level 3 – inputs are not observable in the market and include management’s judgments about the assumptions market participants would use in pricing the asset or liability. For instruments measured using Level 3 inputs, a reconciliation of the beginning and ending balances is disclosed. The following tables summarize the fair values by input hierarchy of items measured at fair value on a recurring basis on our balance sheets (in thousands). Level 1 Level 2 Level 3 Total Total liabilities at fair value, as of December 31, 2016 - derivative warrant liabilities $ - $ - $ 1,527 $ 1,527 Warrants accounted for as derivative liabilities were valued using the lattice model each reporting period and the resultant change in fair value is recorded in net income (loss). The lattice model required us to assess the probability of future issuance of equity instruments at a price lower than the current exercise price of the warrants. The risk-free interest rate is determined by reference to the treasury yield curve rate of instruments with the same term as the warrant. Additional assumptions that were used to calculate fair value follow. Year Ended December 31, 2016 Risk-free interest rate 0.6% -1.9% (1.6% weighted average) Expected volatility 64% (64% weighted average) The following tables summarize the changes in Level 3 items measured at fair value on a recurring basis (in thousands): Total Level 3 Fair Value Fair Value as of Beginning of Year Total and Unrealized Issuance of New Instruments Reclassify to Equity (Deficit) Conversion to Common Stock Fair Value, at End of Year Gains (Losses) on Instruments Still Held (1 ) 2017, derivative warrant liabilities $ (1,527 ) $ 669 $ (7,917 ) $ 7,980 $ 795 $ - $ - 2016, derivative warrant liabilities $ (678 ) $ 1,625 $ (2,474 ) $ - $ - $ (1,527 ) $ (849 ) (1) Included in change in fair value of derivative warrant liabilities in net income (loss).

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2017
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 12. COMMITMENTS AND CONTINGENCIES Employment Contracts and Severance Payments In the normal course of business, we periodically enter into employment agreements which incorporate indemnification provisions. While the maximum amount to which we may be exposed under such agreements cannot be reasonably estimated, we maintain insurance coverage, which we believe will effectively mitigate our obligations under these indemnification provisions. No amounts have been recorded in our financial statements with respect to any obligations under such agreements. We have employment contracts with certain officers and key management that include provisions for potential severance payments in the event of without-cause terminations or terminations under certain circumstances after a change in control. In addition, vesting of outstanding nonvested equity grants would accelerate following a change in control. In November 2016, we entered into an agreement settling matters with our former chief executive officer related to his separation of employment and termination from our board of directors in November 2016. Pursuant to this agreement we paid the former executive severance of $0.3 million in 2016, $0.4 million in 2017. In 2016 we expensed the total $0.7 million associated with the agreement. Leases We lease certain properties under various operating lease arrangements that expire over the next 16 years. These leases generally provide us with the option to renew the lease at the end of the lease term. We incurred rent expense of $0.4 million in 2017 and $0.6 million in 2016. Future minimum payments under these commitments as of December 31, 2017, are as follows (in thousands): 2018 $ 386 2019 377 2020 384 2021 394 2022 404 Thereafter 2,336 Total minimum lease payments $ 4,281 In March 2018, we entered into a triple net lease for approximately 5,380 square feet of office space in The Woodlands, Texas. We expect to move into the space in the second quarter of 2018. The initial term of the lease is sixty-five months and rent is abated for the first five months. Minimum monthly base rents total $0.1 million per year during the initial term of the lease. We expect to recognize rent expense of $0.1 million per year for base rent, plus additional amounts for operating expenses, real estate taxes and other items. We may extend the term of the lease for an additional five-year period at a fair market base rent, as defined in the agreement. From time to time we are involved in litigation incidental to the conduct of our business. These matters may relate to employment and labor claims, patent and intellectual property claims, claims of alleged non-compliance with contract provisions and claims related to alleged violations of laws and regulations. When applicable, we record accruals for contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations. Defense costs are expensed as incurred and are included in professional fees.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2017
RELATED PARTY TRANSACTIONS [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 13. RELATED PARTY TRANSACTIONS Entities beneficially owned by Baruch Halpern, a director, invested in our subordinated notes and related warrants prior to 2016. Throughout the first six months of 2017, Mr. Halpern beneficially held approximately 43% of our outstanding subordinated debt which was repaid in full in July 2017 from the proceeds of the sale of HN. The warrants remain outstanding. See Note 9 for information related to the modification of the subordinated notes, repricing of related warrants and the issuance of warrants to subordinated note holders in February 2017. In 2017 and 2016, we paid $0.2 million and $0.3 million of interest on the subordinated notes. In 2017 and 2016, we expensed $0.1 million and $0.3 million of interest on the subordinated notes. As discussed in Note 9, in September 2017, we issued and sold 2,654,732 shares of common stock to Continental Grain Company (CGG). Our director, Ari Gendason is an employee and senior vice president, head of corporate investments of CGG. As of the date of this filing, CGG owns approximate 16% of our outstanding common stock. We have a greed that in connection with each annual or special meeting of our shareholders at which members of our board of directors are to be elected, or any written consent of our shareholders pursuant to which members of the board of directors are to be elected, CGC shall have the right to designate one nominee to our board of directors. In July 2016, we entered into an agreement with (i) LF-RB Management, LLC, Stephen D. Bask, Richard Bellofatto, Edward M. Giles, Michael Goose, Gary L. Herman, Larry Hopfenspirger and Richard Jacinto II (collectively, the LF-RB Group) and (ii) our directors Beth Bronner, Ari Gendason and Brent Rosenthal (together with the LF-RB Group, the Shareholder Group). The LF-RB Group beneficially owns approximately 9.9% of our outstanding stock. Among other things, under the agreement we paid the LF-RB Group $50,000 in cash and issued 100,000 shares of our common stock to the LF-RB Group for out-of-pocket legal fees and other expenses incurred by the LF-RB Group in connection with its solicitation of proxies to elect its designees to our board at the 2016 annual meeting of shareholders. In addition, the agreement requires that until December 31, 2018, we nominate directors Beth Bronner, Ari Gendason and Brent Rosenthal for election to our board of directors and recommend that our shareholders vote to elect these individuals to our board of directors. The Shareholder Group agreed, until December 31, 2018, to vote their respective shares of common stock in accordance with the recommendations of our board of directors.

FAILURE TO COMPLY WITH NASDAQ L

FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS	12 Months Ended
	Dec. 31, 2017
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS [Abstract]
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS	NOTE 14. FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS On August 18, 2016, we received a notification letter from The Nasdaq Stock Market LLC (Nasdaq) indicating that we had failed to comply with the minimum stockholders’ equity requirement of Nasdaq Listing Rule 5550(b)(1). Nasdaq Listing Rule 5550(b)(1) requires that companies listed on the Nasdaq Capital Market maintain a minimum of $2.5 million in stockholders’ equity for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1) April 24, 2017, we received a decision letter from Nasdaq stating that the request we made at a hearing for continued listing had been granted provided that, on or before May 15, 2017, we had announced that our equity was over $2.5 million (it was $7.9 million as of March 31, 2017). As reported herein, our equity is $14.7 million and exceeds the minimum as of December 31, 2017. On March 10, 2017, we received a notification letter from Nasdaq indicating that we had failed to comply with the minimum bid price requirement of Nasdaq List Rule 5550(a)(2) because our common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive trading days. On August 1, 2017, we received a notification letter from Nasdaq that we regained compliance with Nasdaq List Rule 5550(a)(2) minimum bid price requirement by meeting the closing bid price of $1.00 or more for 10 consecutive trading days on July 31, 2017.

GAIN ON RESOLUTION OF IRGOVEL P

GAIN ON RESOLUTION OF IRGOVEL PURCHASE LITIGATION	12 Months Ended
	Dec. 31, 2017
GAIN ON RESOLUTION OF IRGOVEL PURCHASE LITIGATION [Abstract]
GAIN ON RESOLUTION OF IRGOVEL PURCHASE LITIGATION	NOTE 15. GAIN ON RESOLUTION OF IRGOVEL PURCHASE LITIGATION Under the January 31, 2008, purchase agreement related to the purchase of Irgovel, we deposited $2.0 million into an escrow account to cover contingencies. On March 24, 2016, the $1.9 million in the escrow account was released to us to fund an award owed to us by the sellers of Irgovel. We recognized a gain of $1.6 million in 2016, equal to the difference between the $1.9 million escrow liability and the $0.3 million of resolved pre-acquisition contingencies specifically identified and accrued. As required under an agreement with a lender, we used part of the proceeds to pay $1.0 million of a senior term loan.

SUMMARY OF SIGNIFICANT ACCOUN23

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2017
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation
Use of Estimates	Use of Estimates
Reclassifications	Reclassifications
Cash and Cash Equivalents	Cash and Cash Equivalents
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts
Inventories	Inventories –
Property and Equipment	Property and Equipment We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss is recognized when the undiscounted future cash flows estimated to be generated by the asset to be held and used are not sufficient to recover the unamortized balance of the asset. An impairment loss is recognized based on the difference between the carrying values and estimated fair value. The estimated fair value is determined based on either the discounted future cash flows or other appropriate fair value methods with the amount of any such deficiency charged to operations in the current year. Estimates of future cash flows are based on many factors, including current operating results, expected market trends and competitive influences. Assets to be disposed of by sale are reported at the lower of the carrying amount or fair value, less estimated costs to sell.
Revenue Recognition	Revenue Recognition We make provisions for estimated returns, discounts and price adjustments when they are reasonably estimable. Revenues are net of provisions for estimated returns, routine sales discounts, volume allowances and adjustments. Revenues are also net of taxes collected from customers and remitted to governmental authorities. Amounts billed to a customer in a sale transaction for shipping and handling are reported as revenues and the related costs incurred for shipping are included in cost of goods sold.
Selling, General and Administrative Expenses	Selling, General and Administrative Expenses
Research and Development	Research and Development
Share-Based Compensation	Share-Based Compensation – For awards of nonvested stock, share-based compensation is measured based on the fair value of the award on the date of grant and the corresponding expense is recognized over the period during which an employee is required to provide service in exchange for the reward. Compensation expense related to service-based awards are recognized on a straight-line basis over the requisite service period for the entire award. For restricted stock units, share-based compensation is measured based on the fair value of the award on the date of grant and the corresponding expense is recognized over the period during which an employee is required to provide service in exchange for the reward. Compensation expense related to service-based awards is recognized on a straight-line basis over the requisite service period for the entire award. We account for share-based compensation awards granted to non-employees and consultants by determining the fair value of the awards granted at either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Generally, we value stock options granted to non-employees and consultants using the Black-Scholes-Merton valuation model and stock at the fair value of the award. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of (i) the date at which a commitment for performance by the counterparty to earn the equity instruments is reached or (ii) the date at which the counterparty’s performance is complete. The expense associated with stock awards issued to consultants or other third parties are recognized over the term of service. In the event services are terminated early or we require no specific future performance, the entire amount is expensed. The value is re-measured each reporting period over the requisite service period.
Income Taxes	Income Taxes Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards. A valuation allowance is established, when necessary, to reduce that deferred tax asset if it is more likely than not that the related tax benefits will not be realized. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that may be different from current estimates of the tax liabilities. If our estimate of tax liabilities proves to be less than the ultimate assessment, an additional charge to expense would result. If payment of these amounts ultimately proves to be less than the recorded amounts, the reversal of the liabilities may result in income tax benefits being recognized in the period when it is determined that the liabilities are no longer necessary.
Recent Accounting Guidance	Recent Accounting Guidance Recent accounting standards not yet adopted The following represent the standards not yet adopted that will, or are expected to, result in a significant change in practice and/or have a significant financial impact on us. In May 2014, the Financial Accounting Standards Board (FASB) issued guidance on revenue from contracts with customers to clarify the principles for recognizing revenue, ASU 2014-09, Revenue: Revenue from Contracts with Customers . In February 2016, the FASB issued guidance which changes the accounting for leases, ASU 2016-02, Leases. Recently adopted accounting standards In November 2016, the FASB issued guidance that requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents, ASU 2016-18, Statement of Cash Flows: Restricted Cash

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	12 Months Ended
	Dec. 31, 2017
Healthy Natural Inc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets and liabilities classified as held for sale	The following table summarizes the carrying amount of HN as of the July 14, 2017 sale (in thousands). Accounts receivable, net $ 871 Inventories 1,987 Other current assets 47 Property and equipment 871 Intangible 791 Other 24 Assets 4,591 Accounts payable 759 Accrued expenses 290 Liabilities 1,049 Net assets sold $ 3,542 The following table summarizes the carrying amounts of major classes of HN assets and liabilities classified as held for sale (in thousands). December 31, Accounts receivable, net $ 592 Inventories 1,915 Other current assets held for sale 23 Property and equipment 1,019 Intangible 791 Other noncurrent assets 24 Total assets held for sale $ 4,364 Accounts payable $ 443 Accrued expenses 382 Long term liabilities 73 Total liabilities held for sale $ 898
Income (loss) from discontinued operations	The following table summarizes the major line items included in the income (loss) from discontinued operations for HN (in thousands). Years Ended December 31 2017 2016 Revenues $ 9,902 $ 19,678 Cost of goods sold (6,651 ) (13,158 ) Selling, general and administrative expenses (462 ) (1,440 ) Income from operations, before income taxes 2,789 5,080 Income tax expense (1,048 ) (1,864 ) Income from operations, net of tax 1,741 3,216 Gain on sale, net of $4.7 million income tax expense 8,164 - Income from discontinued operations, net of tax $ 9,905 $ 3,216
Cash flows from discontinued operations	The following table summarizes the major line items included in cash flows from discontinued operations of HN (in thousands). Years Ended December 31 2017 2016 Net cash provided by operating activities $ 2,403 $ 5,829 Net cash provided by (used in) investing activities 16,693 (99 ) Net cash used in financing activities (52 ) - Net cash provided to continuing operations $ (19,044 ) $ (5,730 )
Summary of other data	The following table summarizes other data for HN (in thousands). Years Ended December 31 2017 2016 Depreciation included in cost of goods sold $ 96 $ 175 Depreciation included in selling, general and administrative expenses 49 72 Amortization included in selling, gneral and administrative expenses - 863 Capital expenditures 18 100
Nutra SA [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Assets and liabilities classified as held for sale	The following table summarizes the estimated carrying amount of the Nutra SA net liabilities disposed as of the November 28, 2017, disposal date and the components of the Nutra SA loss on disposal (in thousands). Cash $ 20 Accounts receivable, net 653 Inventories 630 Other current assets 413 Property and equipment 10,070 Other 1,435 Accounts payable (2,560 ) Accrued expenses (7,878 ) Debt (7,345 ) Net liabilities disposed (4,562 ) Foreign curency translation adjustment 4,218 Redeemable noncontrolling interest 1,663 Payments to purchaser at disposal 540 Other 37 Loss on disposal of Nutra SA 1,896 Income tax benefit (694 ) Loss on disposal of Nutra SA, net of tax $ 1,202 The following table summarizes the carrying amounts of major classes of Nutra SA assets and liabilities classified as held for sale as of December 31, 2016 (in thousands). December 31, Cash and cash equivalents $ 109 Accounts receivable, net (restricted) 398 Inventories 925 Other current asssets 373 Property and equipment, net (restricted $2,662) 10,889 Other noncurrent assets 1,327 Total assets held for sale $ 14,021 Accounts payable $ 2,553 Accrued expenses 5,607 Current maturities of long-term debt (nonrecourse) 6,816 Total liabilities held for sale $ 14,976
Income (loss) from discontinued operations	The following table summarizes the major line items included in income (loss) from discontinued operations for Nutra SA (in thousands). Years Ended December 31 2017 2016 Revenues $ 12,209 $ 6,744 Cost of goods sold (12,517 ) (8,423 ) Selling, general and administrative expenses (3,188 ) (2,255 ) Goodwill impairment - (3,024 ) Other expense (1,224 ) (1,378 ) Loss from discontinued operations, before income taxes (4,720 ) (8,336 ) Income taxes - - Loss from operations, net of tax (4,720 ) (8,336 ) Loss on dispoal, net of $0.7 million taxes (1,202 ) - Loss form discontinud operations, ne tof tax $ (5,922 ) $ (8,336 )
Cash flows from discontinued operations	The following table summarizes the major line items included in cash flows from Nutra SA (in thousands). Years Ended December 31 2017 2016 Net cash used in operating activities $ (1,152 ) $ (1,310 ) Net cash used in investing activities (692 ) (257 ) Net cash provided by financing activities 1,114 907 Effect of exchange rate changes 154 103 Net cash provided by continuing operations $ (576 ) $ (557 )
Summary of other data	The following table summarizes other data for Nutra SA (in thousands). Years Ended December 31 2017 2016 Depreciation included in cost of goods sold $ 897 $ 932 Depreciation included in selling, general and administrative expenses 56 57 Capital expenditures 142 257

INCOME (LOSS) PER SHARE (EPS) (

INCOME (LOSS) PER SHARE (EPS) (Tables)	12 Months Ended
	Dec. 31, 2017
INCOME (LOSS) PER SHARE (EPS) [Abstract]
Reconciliation of EPS computations	Below are reconciliations of the numerators and denominators in the EPS computations. Years Ended December 31 2017 2016 NUMERATOR (in thousands): Basic and diluted - loss from continuing operations $ (10,185 ) $ (6,130 ) Dividend on preferred stock--beneficial conversion feature (778 ) (551 ) Basic and diluted - adjusted loss from continuing operations $ (10,963 ) $ (6,681 ) DENOMINATOR (in thousands): Basic EPS - weighted average number of common shares outstanding 11,923,923 9,338,370 Effect of dilutive securities outstanding - - Diluted EPS - weighted average number of shares outstanding 11,923,923 9,338,370 Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive: Stock options 514,961 305,355 Warrants 21,588,045 10,308,778 Convertible preferred stock 2,529,872 1,708,791 Restricted stock units 601,986 - Weighted average number of nonvested share of common stock not included in diluted EPS because effect would be antidilutive 1,249,234 1,132,724

CONCENTRATION OF RISK (Tables)

CONCENTRATION OF RISK (Tables)	12 Months Ended
	Dec. 31, 2017
CONCENTRATIONS OF RISK [Abstract]
Concentrations of risk	Revenues and accounts receivable from significant customers (customers with revenue or accounts receivable in excess of 10% of consolidated totals) are stated below as a percent of consolidated totals. Customer A B C % of revenue, 2017 17% 14% 8% % of revenue, 2016 14% 15% 12% % of accounts receivable, as of December 31, 2017 25% 0% 7% % of accounts receivable, as of December 31, 2016 28% 0% 7%
Revenues by geographic area	The following table presents revenues by geographic area shipped to (in thousands). Years Ended December 31 2017 2016 United States $ 12,196 $ 11,806 Other international 1,159 1,176 Revenues $ 13,355 $ 12,982
Revenues by product line	T Years Ended December 31 2017 2016 Food $ 7,525 $ 7,643 Animal nutrition 5,830 5,339 Revenues $ 13,355 $ 12,982

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2017
PROPERTY AND EQUIPMENT [Abstract]
Property and equipment	December 31 2017 2016 Estimated Useful Lives Land $ 237 $ 237 Furniture and fixtures 311 306 5-7 years Plant 6,580 6,582 30 years, or life of lease Computer and software 1,207 1,147 3-5 years Leasehold improvements 274 261 4-7 years or life of lease Machinery and equipment 8,677 7,274 5-10 years Property and equipment, cost 17,286 15,807 Less accumulated depreciation 9,436 8,782 Property and equipment, net $ 7,850 $ 7,025

DEBT (Tables)

DEBT (Tables)	12 Months Ended
	Dec. 31, 2017
DEBT [Abstract]
Current and long-term debt	The following table summarizes current and long-term portions of debt as of December 31, 2017 and 2016 (in thousands): 2017 2016 Senior revolving loan $ - $ 1,725 Senior term loan, net - 917 Subordinated notes - 6,310 Other 16 75 16 9,027 Current portion 4 3,063 Long-term portion $ 12 $ 5,964

EQUITY, SHARE-BASED COMPENSAT29

EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONS (Tables)	12 Months Ended
	Dec. 31, 2017
EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONS [Abstract]
Share-based compensation expenses included in selling, general and administrative expenses	The following table provides a detail of share-based compensation expense (in thousands). Years Ended December 31 2017 2016 Stock options $ 176 $ 243 Common stock, vested at issuance and nonvested at issuance 744 768 Restricted stock units 27 - Compensation expense related to common stock awards issued under equity incentive plans $ 947 $ 1,011
Summary of information related to outstanding warrants	The following table summarizes information related to outstanding warrants: December 31, 2017 December 31, 2016 Range of Exercise Prices Type of Warrant Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Under Warrants, Exercisable Cashless Shares Under Warrants Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) (4 ) $ 0.96 Equity 12,972,832 0.96 4.1 3,774,344 - - - $ 1.50 to $1.60 Liability (1)(3) - - - - 1,789,868 1.52 1.3 $ 1.60 Equity (1) 300,000 1.60 2.4 300,000 - - - $ 2.00 Liability (2) - - - - 2,660,000 2.00 4.6 $ 2.00 Equity 2,660,000 2.00 3.6 - - - - $ 5.25 Liability (2) - - - - 25,000 5.25 3.6 $ 5.25 to $5.87 Equity 3,156,670 5.33 1.7 359,536 4,296,339 5.36 2.7 $ 6.55 to $16.80 Equity 2,067,771 6.61 1.0 190,899 2,067,771 6.61 2.0 21,157,273 $ 2.30 3.4 4,624,779 10,838,978 $ 4.14 2.8 (1) Includes a warrant for the purchase of up to purchase 300,000 shares of common stock which contains a most favored nations anti-dilution provision. Under that provision, in the event we issue warrants and/or other convertible instruments with anti-dilution provisions with respect to the exercise price of the warrant or the conversion price of the convertible instrument, we will be required to provide the same anti-dilution provision in this warrant and may be required to lower the exercise price on this warrant and/or increase the number of shares underlying this warrant. The warrant also contains a provision in effect until November 2017 which gave the holder the right to demand a net cash settlement in the event of a fundamental transaction (as defined in the agreement). The warrant was classified as derivative warrant liability in our balance sheets due to that provision as of December 31, 2016, and was reclassified to equity (deficit) in November 2017 when the provision expired. (2) The warrants were classified as derivative warrant liabilities in our balance sheets due to the Share Sequencing as of December 31, 2016, and were reclassified to equity (deficit) effective March 31, 2017. (3) Includes warrants for the purchase 1,489,868 shares of common stock, at December 31, 2016, which contained full ratchet anti-dilution provisions. The warrants were classified as derivative warrant liability in our balance sheets due to that provision as of December 31, 2016, and were exercised in 2017. (4) Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature. The shares listed, represent the shares holders could exercise cashless as of December 31, 2017. If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise. Should we fail to maintain a registration statement for the resale of shares under certain other warrant, the shares under those warrants may be exercisable using a cashless exercise feature.
Summary of warrant activity	The following table summarizes warrant activity. Equity Warrants Liability Warrants Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Underlying Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding, December 31, 2015 6,367,139 $ 4.02 2.8 726,489 $ 5.24 2.9 Issued - NA NA 2,685,000 2.03 5.0 Impact of repricing senior lender warrants: Prior to repricing - NA NA (300,000 ) 5.25 3.9 After repricing - NA NA 300,000 1.80 3.9 Prior to repricing - NA NA (300,000 ) 1.80 3.7 After repricing - NA NA 300,000 1.60 3.7 Impact of anti-dilution clauses: Prior to impact - NA NA (426,489 ) 5.24 1.8 After impact - NA NA 1,489,868 1.50 1.8 Exercised - NA NA - NA NA Forfeited, expired or cancelled (3,029 ) 46.80 - - NA NA Outstanding, December 31, 2016 6,364,110 5.77 2.44 4,474,868 1.82 3.3 Issued 25,000 0.96 5.01 11,783,163 0.96 5.0 Impact of repricing senior debenture purchaser warrants: Prior to repricing (875,000 ) 5.49 2.1 - NA NA After repricing 875,000 0.96 5.5 - NA NA Impact of repricing subordinated note holder warants: Prior to repricing (289,669 ) 5.25 3.3 - NA NA After repricing 289,669 0.96 3.3 - NA NA Impact of anti-dilution clauses: Prior to impact - NA NA (1,489,868 ) 1.50 0.8 After impact - NA NA 2,327,919 0.96 0.8 Transfer from liability to equity 14,768,163 1.16 4.8 (14,768,163 ) 1.16 4.8 Exercised - NA NA (2,327,919 ) 0.96 - Forfeited, expired or cancelled - NA NA - NA NA Outstanding, December 31, 2017 21,157,273 $ 2.30 3.4 - $ - - Exercisable, December 31, 2017 21,157,273 $ 2.30 3.4 - $ - -
Summary of stock option activity	A summary of stock option activity follows. Shares Under Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Outstanding, December 31, 2015 357,797 $ 12.12 7.9 Granted - NA NA Exercised - NA NA Forfeited, expired or cancelled (186,986 ) 8.88 6.5 Outstanding, December 31, 2016 170,811 8.83 7.2 Granted 481,500 0.79 10.0 Exercised - NA NA Forfeited, expired or cancelled (12,652 ) 3.62 8.1 Outstanding, December 31, 2017 639,659 $ 2.91 8.5
Weighted-average assumptions used in valuing stock options	The following are the assumptions used in valuing the 2017 stock option grants: Year Ended December 31, 2017 Assumed volatility 85% - 87% (87% weighted average) Assumed risk free interest rate 1.8% - 2.0% (2.0% weighted average) Average expected life of options (in years) 6.2 (6.2 weighted average) Expected dividends -
Summary of information related to outstanding and exercisable options	The following table summarizes information related to outstanding and exercisable stock options as of December 31, 2017: Outstanding Exercisable Range of Exercise Prices Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Shares Underlying Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) $ 0.76 to $0.91 450,500 $ 0.83 9.3 53,332 $ 0.79 9.2 $ 1.09 to $1.98 31,000 1.27 9.4 5,000 1.98 7.9 $ 2.91 to $2.97 19,000 2.97 7.6 14,828 2.97 7.6 $ 3.47 34,790 3.47 7.5 32,429 3.47 7.5 $ 4.27 to $6.00 55,243 4.63 6.6 55,147 4.83 6.6 $ 16.00 42,335 16.00 3.9 42,335 16.00 3.9 $ 28.00 to $74.00 6,791 49.94 3.6 6,791 49.94 3.6 639,659 $ 2.91 8.5 209,862 $ 7.06 6.8
Summary of RSA activity	Shares Issued to Employees and Directors Weighted Average Grant Date Fair Value Fair Value (in thousands) Weighted Average Remaining Vesting (Years) Unrecognized Stock Compensation (in thousands) (a) Nonvested at December 31, 2015 324,229 $ 4.25 $ 616.0 1.66 $ 796.3 Granted 174,825 1.46 255.00 Vested (242,215 ) (b) 4.16 323.00 Forfeited - NA NA Nonvested at December 31, 2016 256,839 2.44 265.00 0.7 284.6 Granted 380,541 0.92 349.00 Vested (252,636 ) (c) 2.42 220.00 Forfeited - NA NA Nonvested at December 31, 2017 384,744 (d) $ 0.94 $ 569.0 0.5 $ 176.3 (a) Represents pre-tax fair value, based on our closing stock prices, which would have been received by the holders of the stock had all such holders sold their underlying shares on the date indicated, the dates of grant or the dates of vesting, as applicable. (b) Includes 147,836 shares, for which vesting was accelerated in November 2016, based on the terms of a severance agreement. (c) Includes 73,608 shares, for which vesting was accelerated in June 2017, based on the terms of a severance agreement. (d) Excludes 890,708 shares, issued to a supplier, nonvested and unearned as of December 31, 2017. The shares are being held in escrow until earned (as defined in our agreement) by the supplier at a fixed price of $2.80 per share

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2017
INCOME TAXES [Abstract]
Deferred tax asset (Liability)	Deferred tax asset (liability) is comprised of the following (in thousands): December 31 2017 2016 Net operating loss carryforwards $ 5,560 $ 7,946 Capital loss 7,030 363 Stock options and warrants 322 724 Property 499 743 Intangible assets 89 (252 ) Capitalized expenses 142 342 Debt and deferred financing - 178 Other 230 466 Net deferred tax assets 13,872 10,510 Less: Valuation allowance (13,872 ) (10,510 ) Deferred tax asset (liability) $ - $ -
Summary of change in the valuation allowance	The following table summarizes the change in the valuation allowance (in thousands). Years Ended December 31 2017 2016 Vaulation allowances at beginning of year $ 10,510 $ 5,726 Net operating loss 4,358 5,021 Expiration of net operating losses and limitations 2,353 (105 ) Effect of federal rate reduction from 34% to 21% (7,079 ) - Capital loss from redemption of Nutra SA interests 11,058 - Other adjusments (1,384 ) (132 ) Change in valuation allowance, before transfer 9,306 4,784 Transferred from discontinued operations (5,944 ) - Valuation allowances at end of year $ 13,872 $ 10,510
Components of income tax benefit	The components of income tax benefit follow (in thousands). Years Ended December 31 2017 2016 Current: State $ 16 $ 45 Deferred: Federal (4,684 ) (1,732 ) State (362 ) (137 ) Total deferred (5,046 ) (1,869 ) Income tax benefit $ (5,030 ) $ (1,824 )
Effective income tax rate reconciliation	Reconciliations between the amount computed by applying the U.S. federal statutory tax rate (34%) to loss before income taxes, and income tax benefit follows (in thousands): Years Ended December 31 2017 2016 Income tax benefit at federal statutory rate $ (5,173 ) $ (2,704 ) Increase (decrease) resulting from: State tax benefit, net of federal tax effect (400 ) (214 ) Effect of federal rate reduction from 34% to 21% 7,079 - Change in valuation allowance 9,306 4,784 Capital loss from redemption of Nutra SA interests (11,058 ) - Expiration of net operating losses (310 ) 105 Reduction in deferred balances for forfeited, expired or cancelled options 317 168 Nontaxable fair value adjustment (234 ) (553 ) Nondeductible expenses 55 (465 ) Other adjustments to deferred balances - (994 ) Allocated from discontinud operations (5,046 ) (1,864 ) Other 434 (86 ) Income tax benefit $ (5,030 ) $ (1,824 )

FAIR VALUE MEASUREMENT (Tables)

FAIR VALUE MEASUREMENT (Tables)	12 Months Ended
	Dec. 31, 2017
FAIR VALUE MEASUREMENT [Abstract]
Fair values by input hierarchy of items measured at fair value on a recurring basis	The following tables summarize the fair values by input hierarchy of items measured at fair value on a recurring basis on our balance sheets (in thousands). Level 1 Level 2 Level 3 Total Total liabilities at fair value, as of December 31, 2016 - derivative warrant liabilities $ - $ - $ 1,527 $ 1,527
Additional assumptions used to calculate fair value	Additional assumptions that were used to calculate fair value follow. Year Ended December 31, 2016 Risk-free interest rate 0.6% -1.9% (1.6% weighted average) Expected volatility 64% (64% weighted average)
Changes in level 3 items measured at fair value	The following tables summarize the changes in Level 3 items measured at fair value on a recurring basis (in thousands): Total Level 3 Fair Value Fair Value as of Beginning of Year Total and Unrealized Issuance of New Instruments Reclassify to Equity (Deficit) Conversion to Common Stock Fair Value, at End of Year Gains (Losses) on Instruments Still Held (1 ) 2017, derivative warrant liabilities $ (1,527 ) $ 669 $ (7,917 ) $ 7,980 $ 795 $ - $ - 2016, derivative warrant liabilities $ (678 ) $ 1,625 $ (2,474 ) $ - $ - $ (1,527 ) $ (849 ) (1) Included in change in fair value of derivative warrant liabilities in net income (loss).

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2017
COMMITMENTS AND CONTINGENCIES [Abstract]
Future minimum payments under operating lease commitments	Future minimum payments under these commitments as of December 31, 2017, are as follows (in thousands): 2018 $ 386 2019 377 2020 384 2021 394 2022 404 Thereafter 2,336 Total minimum lease payments $ 4,281

LIQUIDITY AND MANAGEMENT'S PL33

LIQUIDITY AND MANAGEMENT'S PLAN (Details) - USD ($) $ in Thousands	2 Months Ended	3 Months Ended		12 Months Ended
	Mar. 15, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Liquidity and Management's Plan [Line Items]
Increase in cash and cash equivalents and restricted cash				$ 6,636
Cash and cash equivalents and restricted cash		$ 6,978	$ 342	6,978	$ 342	$ 2,887
Decrease in operating loss				(3,200)
Operating loss				(6,097)	(9,257)
Net cash used in operating activities of continuing operations				(5,025)	(8,454)
Debt outstanding		16	9,027	16	9,027
Interest payment				$ 811	$ 1,849
Operating expenses		$ 2,400	$ 3,000
Subsequent Event [Member]
Liquidity and Management's Plan [Line Items]
Interest payment	$ 0
Subsequent Event [Member] | Maximum [Member]
Liquidity and Management's Plan [Line Items]
Debt outstanding	$ 100

BUSINESS (Details)

BUSINESS (Details)	Dec. 31, 2017Location
BUSINESS [Abstract]
Number of locations	3
Number of locations in california	2
Number of locations in louisiana	1

DISCONTINUED OPERATIONS, Health

DISCONTINUED OPERATIONS, Healthy Natural (HN) (Details) - Healthy Natural Inc [Member] - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale of assets	$ 18,300
Restriction period to engage in business conducted by sold entity		5 years
Escrow for working capital adjustments		$ 200
Escrow for indemnity claims		600
Estimated working capital adjustments		300
Net carrying value of discontinued operations		16,700
Gain on sale of business		8,164	$ 0
Tax provision for gain on sale of business		$ 4,700

DISCONTINUED OPERATIONS, Carryi

DISCONTINUED OPERATIONS, Carrying Value of Assets and Liabilities, Healthy Natural (HN) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jul. 14, 2017	Dec. 31, 2016
Major Classes of Assets and Liabilities Classified as Held for Sale [Abstract]
Long term liabilities	$ 0		$ 73
Healthy Natural Inc [Member]
Major Classes of Assets and Liabilities Classified as Held for Sale [Abstract]
Accounts receivable, net		$ 871	592
Inventories		1,987	1,915
Other current assets held for sale		47	23
Property and equipment		871	1,019
Intangible		791	791
Other noncurrent assets		24	24
Total assets held for sale		4,591	4,364
Accounts payable		759	443
Accrued expenses		290	382
Long term liabilities			73
Total liabilities held for sale		1,049	$ 898
Net assets sold		$ 3,542

DISCONTINUED OPERATIONS, Income

DISCONTINUED OPERATIONS, Income (Loss) from Discontinued Operations, Healthy Natural (HN) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income (Loss) from Discontinued Operations [Abstract]
Income (loss) from discontinued operations, net of tax	$ 3,983	$ (5,120)
Healthy Natural Inc [Member]
Income (Loss) from Discontinued Operations [Abstract]
Revenues	9,902	19,678
Cost of goods sold	(6,651)	(13,158)
Selling, general and administrative expenses	(462)	(1,440)
Income (loss) from discontinued operations, before income taxes	2,789	5,080
Income tax expense	(1,048)	(1,864)
Income (loss) from operations, net of tax	1,741	3,216
Gain (loss) on sale, net of income tax expense	8,164	0
Income (loss) from discontinued operations, net of tax	9,905	$ 3,216
Tax expense (benefit) on gain (loss) from disposal	$ 4,700

DISCONTINUED OPERATIONS, Cash F

DISCONTINUED OPERATIONS, Cash Flows from Discontinued Operations, Healthy Natural (HN) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Net Cash Provided by (Used in) Discontinued Operations [Abstract]
Net cash provided by operating activities	$ 1,251	$ 4,519
Net cash provided by (used in) investing activities	16,001	(356)
Net cash provided (used) by financing activities	1,062	907
Healthy Natural Inc [Member]
Net Cash Provided by (Used in) Discontinued Operations [Abstract]
Net cash provided by operating activities	2,403	5,829
Net cash provided by (used in) investing activities	16,693	(99)
Net cash provided (used) by financing activities	(52)	0
Net cash provided (by) to continuing operations	$ (19,044)	$ (5,730)

DISCONTINUED OPERATIONS, Other

DISCONTINUED OPERATIONS, Other Data, Healthy Natural (HN) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Selling, General and Administrative Expenses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	$ 56	$ 57
Amortization	0	863
Healthy Natural Inc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital Expenditure	18	100
Healthy Natural Inc [Member] | Cost of Goods Sold [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	96	175
Healthy Natural Inc [Member] | Selling, General and Administrative Expenses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	$ 49	$ 72

DISCONTINUED OPERATIONS, Nutra

DISCONTINUED OPERATIONS, Nutra SA (Details) - Nutra SA [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Investors' average interest in Nutra SA during the period	36.00%	32.00%
Property and equipment restricted		$ 2,662

DISCONTINUED OPERATIONS, Compon

DISCONTINUED OPERATIONS, Components of Loss on Disposal, Nutra SA (Details) - Nutra SA [Member] - USD ($) $ in Thousands	Nov. 28, 2017	Dec. 31, 2016
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash	$ 20	$ 109
Accounts receivable, net (restricted)	653	398
Inventories	630	925
Other current assets	413	373
Property and equipment	10,070	10,889
Other	1,435	1,327
Accounts payable	(2,560)	(2,553)
Accrued expenses	(7,878)	(5,607)
Current maturities of long-term debt (nonrecourse)	(7,345)	(6,816)
Net liabilities disposed	(4,562)	$ (14,976)
Foreign currency translation adjustment	4,218
Redeemable noncontrolling interest	1,663
Payments to purchaser at disposal	540
Other	37
Loss on disposal of Nutra SA	1,896
Income tax benefit	(694)
Loss on disposal of Nutra SA, net of tax	$ 1,202

DISCONTINUED OPERATIONS, Carr42

DISCONTINUED OPERATIONS, Carrying Value of Assets and Liabilities, Nutra SA (Details) - Nutra SA [Member] - USD ($) $ in Thousands	Nov. 28, 2017	Dec. 31, 2016
Major Classes of Assets and Liabilities Classified as Held for Sale [Abstract]
Cash	$ 20	$ 109
Accounts receivable, net (restricted)	653	398
Inventories	630	925
Other current assets	413	373
Property and equipment, net (restricted $2,662)	10,070	10,889
Other	1,435	1,327
Total assets held for sale		14,021
Accounts payable	2,560	2,553
Accrued expenses	7,878	5,607
Current maturities of long-term debt (nonrecourse)	7,345	6,816
Total liabilities held for sale	$ 4,562	$ 14,976

DISCONTINUED OPERATIONS, Inco43

DISCONTINUED OPERATIONS, Income (Loss) from Discontinued Operations, Nutra SA (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income (Loss) from Discontinued Operations [Abstract]
Income (loss) from discontinued operations, net of tax	$ 3,983	$ (5,120)
Nutra SA [Member]
Income (Loss) from Discontinued Operations [Abstract]
Revenues	12,209	6,744
Cost of goods sold	(12,517)	(8,423)
Selling, general and administrative expenses	(3,188)	(2,255)
Goodwill impairment	0	(3,024)
Other expense	(1,224)	(1,378)
Income (loss) from discontinued operations, before income taxes	(4,720)	(8,336)
Income taxes	0	0
Income (loss) from operations, net of tax	(4,720)	(8,336)
Loss on dispoal, net of $0.7 million taxes	(1,202)	0
Income (loss) from discontinued operations, net of tax	$ (5,922)	$ (8,336)

DISCONTINUED OPERATIONS, Cash44

DISCONTINUED OPERATIONS, Cash Flows from Discontinued Operations, Nutra SA (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Net Cash Provided by (Used in) Discontinued Operations [Abstract]
Net cash provided by operating activities	$ 1,251	$ 4,519
Net cash used in investing activities	16,001	(356)
Net cash provided by financing activities	1,062	907
Effect of exchange rate changes	154	103
Nutra SA [Member]
Net Cash Provided by (Used in) Discontinued Operations [Abstract]
Net cash provided by operating activities	(1,152)	(1,310)
Net cash used in investing activities	(692)	(257)
Net cash provided by financing activities	1,114	907
Effect of exchange rate changes	154	103
Net cash provided by continuing operations	$ (576)	$ (557)

DISCONTINUED OPERATIONS, Othe45

DISCONTINUED OPERATIONS, Other Data, Nutra SA (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Selling, General and Administrative Expenses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	$ 56	$ 57
Nutra SA [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Capital Expenditure	142	257
Nutra SA [Member] | Cost of Goods Sold [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Depreciation	$ 897	$ 932

INCOME (LOSS) PER SHARE (EPS)46

INCOME (LOSS) PER SHARE (EPS) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
NUMERATOR [Abstract]
Basic and diluted - loss from continuing operations	$ (10,185)	$ (6,130)
Dividends on preferred stock--beneficial conversion feature	(778)	(551)
Basic and diluted - adjusted loss from continuing operations	$ (10,963)	$ (6,681)
DENOMINATOR [Abstract]
Basic EPS - weighted average number of common shares outstanding (in shares)	11,923,923	9,338,370
Effect of dilutive securities outstanding (in shares)	0	0
Diluted EPS - weighted average number of shares outstanding (in shares)	11,923,923	9,338,370
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	514,961	305,355
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	21,588,045	10,308,778
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	2,529,872	1,708,791
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	601,986	0
Nonvested Shares of Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of shares of common stock which could be purchased with weighted average outstanding securities not included in diluted EPS because effect would be antidilutive (in shares)	1,249,234	1,132,724

CONCENTRATION OF RISK (Details)

CONCENTRATION OF RISK (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)Supplier	Dec. 31, 2016USD ($)
Concentration Risk [Line Items]
Revenues	$ 13,355	$ 12,982
Number of suppliers, rice bran | Supplier	4
Reportable Geographic Segment [Member] | United States [Member]
Concentration Risk [Line Items]
Revenues	$ 12,196	11,806
Reportable Geographic Segment [Member] | Other International [Member]
Concentration Risk [Line Items]
Revenues	1,159	1,176
Operating Segments [Member] | Food [Member]
Concentration Risk [Line Items]
Revenues	7,525	7,643
Operating Segments [Member] | Animal Nutrition [Member]
Concentration Risk [Line Items]
Revenues	$ 5,830	$ 5,339
Cost of Goods Sold [Member] | Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	37.00%	33.00%
Customer A [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	17.00%	14.00%
Customer A [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	25.00%	28.00%
Customer B [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	14.00%	15.00%
Customer B [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	0.00%	0.00%
Customer C [Member] | Revenue [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	8.00%	12.00%
Customer C [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	7.00%	7.00%

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, cost	$ 17,286	$ 15,807
Less accumulated depreciation	9,436	8,782
Property and equipment, net	7,850	7,025
Depreciation expense	600	800
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, cost	237	237
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, cost	$ 311	306
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Plant [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, cost	$ 6,580	6,582
Estimated useful lives	30 years
Computer and Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, cost	$ 1,207	1,147
Computer and Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Computer and Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, cost	$ 274	261
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	4 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, cost	$ 8,677	$ 7,274
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years

DEBT (Details)

DEBT (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended	12 Months Ended
	Jul. 31, 2017	Feb. 28, 2017	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Total debt				$ 16	$ 9,027
Current portion				4	3,063
Long-term portion				12	5,964
Loss on extinguishment of debt	$ (6,600)			(8,290)	0
Senior Revolving Loan [Member]
Debt Instrument [Line Items]
Total debt				0	1,725
Senior Term Loan, Net [Member]
Debt Instrument [Line Items]
Total debt				0	917
Subordinated Notes [Member]
Debt Instrument [Line Items]
Total debt				0	$ 6,310
Loss on extinguishment of debt		$ (1,500)
Subordinated Notes [Member] | HN [Member]
Debt Instrument [Line Items]
Aggregate principal amount				6,000
Carrying value of debt				$ 5,300
Subordinated Notes [Member] | Maturity Due May 2019 [Member]
Debt Instrument [Line Items]
Variable interest rate				7.00%	11.75%
Payment of note principal			$ 200
Payment of accrued note interest			$ 300
Effective interest rate				15.00%
Maturity date of note				May 31, 2019
Other [Member]
Debt Instrument [Line Items]
Total debt				$ 16	$ 75
Senior Debentures [Member]
Debt Instrument [Line Items]
Aggregate principal amount				$ 6,600
Effective interest rate				160.60%
Senior Debentures [Member] | HN [Member]
Debt Instrument [Line Items]
Carrying value of debt				$ 600

EQUITY, SHARE-BASED COMPENSAT50

EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONS (Details)	1 Months Ended	12 Months Ended
	Feb. 28, 2017USD ($)$ / sharesshares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)shares	Jan. 31, 2017shares	Feb. 29, 2016shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in authorized number of shares of common stock (in shares)	50,000,000	50,000,000	50,000,000	25,000,000
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plans | $		$ 947,000	$ 1,011,000
Stock Options [Member]
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plans | $		176,000	243,000
Common Stock, Vested at Issuance and Nonvested at Issuance [Member]
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plans | $		744,000	768,000
Restricted Stock Units [Member]
Share-based compensation expense [Abstract]
Compensation expense related to common stock awards issued under equity incentive plans | $		$ 27,000	$ 0
Series F Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock shares issued (in shares)		0			3,000
Preferred stock shares outstanding (in shares)		0
Preferred stock conversion ratio to common stock	666.66666
Preferred stock, dividend per share (in dollars per share) | $ / shares	$ 0.01
Series G Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock shares issued (in shares)	2,000	630
Preferred stock shares outstanding (in shares)	630	630
Preferred stock conversion ratio to common stock	948.9915
Preferred stock, dividend | $	$ 1,000
Preferred Stock [Member] | Series F Convertible Preferred Stock [Member]
Share-based compensation expense [Abstract]
Change in classification of preferred stock to equity from liability (in shares)		3,000
Preferred Stock [Member] | Series G Convertible Preferred Stock [Member]
Share-based compensation expense [Abstract]
Change in classification of preferred stock to equity from liability (in shares)		2,000

EQUITY, SHARE-BASED COMPENSAT51

EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONS, Warrants Outstanding (Details) - $ / shares		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Summary of information related to outstanding and exercisable warrants [Abstract]
Shares under warrants, outstanding (in shares)		21,157,273	10,838,978
Weighted average exercise price (in dollars per share)		$ 2.30	$ 4.14
Weighted average remaining contractual life		3 years 4 months 24 days	2 years 9 months 18 days
Shares under warrants, exercisable cashless (in shares)	[1]	4,624,779
Warrants issued to purchase common stock (in shares)			1,489,868
Equity Warrants [Member] | $0.96 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)		$ 0.96
Shares under warrants, outstanding (in shares)		12,972,832	0
Weighted average exercise price (in dollars per share)		$ 0.96	$ 0
Weighted average remaining contractual life		4 years 1 month 6 days	0 years
Shares under warrants, exercisable cashless (in shares)	[1]	3,774,344
Equity Warrants [Member] | $1.60 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)	[2]	$ 1.60
Shares under warrants, outstanding (in shares)	[2]	300,000	0
Weighted average exercise price (in dollars per share)	[2]	$ 1.60	$ 0
Weighted average remaining contractual life	[2]	2 years 4 months 24 days	0 years
Shares under warrants, exercisable cashless (in shares)	[1],[2]	300,000
Equity Warrants [Member] | $2.00 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)		$ 2
Shares under warrants, outstanding (in shares)		2,660,000	0
Weighted average exercise price (in dollars per share)		$ 2	$ 0
Weighted average remaining contractual life		3 years 7 months 6 days	0 years
Shares under warrants, exercisable cashless (in shares)	[1]	0
Equity Warrants [Member] | $5.25 to $5.87 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Shares under warrants, outstanding (in shares)		3,156,670	4,296,339
Weighted average exercise price (in dollars per share)		$ 5.33	$ 5.36
Weighted average remaining contractual life		1 year 8 months 12 days	2 years 8 months 12 days
Shares under warrants, exercisable cashless (in shares)	[1]	359,536
Equity Warrants [Member] | $5.25 to $5.87 [Member] | Minimum [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, lower range limit (in dollars per share)		$ 5.25
Equity Warrants [Member] | $5.25 to $5.87 [Member] | Maximum [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)		$ 5.87
Equity Warrants [Member] | $6.55 to $ 16.80 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Shares under warrants, outstanding (in shares)		2,067,771	2,067,771
Weighted average exercise price (in dollars per share)		$ 6.61	$ 6.61
Weighted average remaining contractual life		1 year	2 years
Shares under warrants, exercisable cashless (in shares)	[1]	190,899
Equity Warrants [Member] | $6.55 to $ 16.80 [Member] | Minimum [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, lower range limit (in dollars per share)		$ 6.55
Equity Warrants [Member] | $6.55 to $ 16.80 [Member] | Maximum [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)		16.80
Liability Warrants [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Weighted average exercise price (in dollars per share)		$ 0	$ 1.82	$ 5.24
Weighted average remaining contractual life		0 years	3 years 3 months 18 days	2 years 10 months 24 days
Warrants issued to purchase common stock (in shares)		11,783,163	2,685,000
Liability Warrants [Member] | $1.50 to $1.60 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Shares under warrants, outstanding (in shares)	[2],[3]	0	1,789,868
Weighted average exercise price (in dollars per share)	[2],[3]	$ 0	$ 1.52
Weighted average remaining contractual life	[2],[3]	0 years	1 year 3 months 18 days
Shares under warrants, exercisable cashless (in shares)	[1],[2],[3]	0
Liability Warrants [Member] | $1.50 to $1.60 [Member] | Minimum [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, lower range limit (in dollars per share)	[2],[3]	$ 1.50
Liability Warrants [Member] | $1.50 to $1.60 [Member] | Maximum [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)	[2],[3]	1.60
Liability Warrants [Member] | $2.00 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)	[4]	$ 2
Shares under warrants, outstanding (in shares)	[4]	0	2,660,000
Weighted average exercise price (in dollars per share)	[4]	$ 0	$ 2
Weighted average remaining contractual life	[4]	0 years	4 years 7 months 6 days
Shares under warrants, exercisable cashless (in shares)	[1],[4]	0
Liability Warrants [Member] | $5.25 [Member]
Summary of information related to outstanding and exercisable warrants [Abstract]
Exercise price range, upper range limit (in dollars per share)	[3],[4]	$ 5.25
Shares under warrants, outstanding (in shares)	[4]	0	25,000
Weighted average exercise price (in dollars per share)	[4]	$ 0	$ 5.25
Weighted average remaining contractual life	[4]	0 years	3 years 7 months 6 days
Shares under warrants, exercisable cashless (in shares)	[1],[4]	0
[1]	Under the terms of certain outstanding warrants, the holders may elect to exercise the warrants under a cashless exercise feature. The shares listed, represent the shares holders could exercise cashless as of December 31, 2017. If we register for resale the shares subject to warrants, the holders of some of the warrants may no longer have the right to elect a cashless exercise. Should we fail to maintain a registration statement for the resale of shares under certain other warrant, the shares under those warrants may be exercisable using a cashless exercise feature.
[2]	Includes a warrant for the purchase of up to purchase 300,000 shares of common stock which contains a most favored nations anti-dilution provision. Under that provision, in the event we issue warrants and/or other convertible instruments with anti-dilution provisions with respect to the exercise price of the warrant or the conversion price of the convertible instrument, we will be required to provide the same anti-dilution provision in this warrant and may be required to lower the exercise price on this warrant and/or increase the number of shares underlying this warrant. The warrant also contains a provision in effect until November 2017 which gave the holder the right to demand a net cash settlement in the event of a fundamental transaction (as defined in the agreement). The warrant was classified as derivative warrant liability in our balance sheets due to that provision as of December 31, 2016, and was reclassified to equity (deficit) in November 2017 when the provision expired.
[3]	Includes warrants for the purchase 1,489,868 shares of common stock, at December 31, 2016, which contained full ratchet anti-dilution provisions. The warrants were classified as derivative warrant liability in our balance sheets due to that provision as of December 31, 2016, and were exercised in 2017.
[4]	The warrants were classified as derivative warrant liabilities in our balance sheets due to the Share Sequencing as of December 31, 2016, and were reclassified to equity (deficit) effective March 31, 2017.

EQUITY, SHARE-BASED COMPENSAT52

EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONS, Warrant Activity (Details) - USD ($) $ / shares in Units, $ in Millions	2 Months Ended	12 Months Ended
	Mar. 08, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Shares Under Warrants [Roll Forward]
Issued (in shares)			1,489,868
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)	$ 2.30	$ 4.14
Outstanding at end of period (in dollars per share)		$ 2.30	$ 4.14
Equity and Liability Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life		3 years 4 months 24 days	2 years 9 months 18 days
Exercised		4 years 1 month 6 days
Subsequent Event [Member]
Shares Under Warrants [Roll Forward]
Issued (in shares)	315,000
Exercised (in shares)	(67,395)
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Issued (in dollars per share)	$ 4.73
Exercised (in dollars per share)	$ 0.96
Equity and Liability Warrants, Additional Disclosures [Abstract]
Issued	2 years 4 months 24 days
Expense recognized for the issuances	$ 0.1
Equity Warrants [Member]
Shares Under Warrants [Roll Forward]
Outstanding at beginning of period (in shares)	21,157,273	6,364,110	6,367,139
Issued (in shares)		25,000	0
Impact of repricing senior lender warrants, Prior to repricing (in shares)			0
Impact of repricing senior lender warrants, After repricing (in shares)			0
Impact of repricing senior lender warrants, Prior to repricing (in shares)			0
Impact of repricing senior lender warrants, After repricing (in shares)			0
Impact of repricing senior debenture purchaser warrants, Prior to repricing (in shares)		(875,000)
Impact of repricing senior debenture purchaser warrants, After repricing (in shares)		875,000
Impact of repricing subordinated note holder warrants, Prior to repricing (in shares)		(289,669)
Impact of repricing subordinated note holder warrants, After repricing (in shares)		289,669
Impact of anti-dilution clauses, Prior to impact (in shares)		0	0
Impact of anti-dilution clauses, After impact (in shares)		0	0
Transfer from liability to equity (in shares)		14,768,163
Exercised (in shares)		0	0
Forfeited, expired or cancelled (in shares)		0	(3,029)
Outstanding at end of period (in shares)		21,157,273	6,364,110	6,367,139
Exercisable at end of period (in shares)		21,157,273
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)	$ 2.30	$ 5.77	$ 4.02
Issued (in dollars per share)		0.96
Impact of repricing senior debenture purchaser warrants, Prior to repricing (in dollars per share)		5.49
Impact of repricing senior debenture purchaser warrants, After repricing (in dollars per share)		0.96
Impact of repricing subordinated note holder warrants, Prior to repricing (in dollars per share)		5.25
Impact of repricing subordinated note holder warrants, After repricing (in dollars per share)		0.96
Transfer from liability to equity (in dollars per share)		1.16
Forfeited, expired or cancelled (in dollars per share)			46.80
Outstanding at end of period (in dollars per share)		2.30	$ 5.77	$ 4.02
Exercisable at end of period (in dollars per share)		$ 2.30
Equity and Liability Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life		3 years 4 months 24 days	2 years 5 months 8 days	2 years 9 months 18 days
Issued		5 years 4 days
Impact of repricing senior debenture purchaser warrants, Prior to repricing		2 years 1 month 6 days
Impact of repricing senior debenture purchaser warrants, After repricing		5 years 6 months
Impact of repricing subordinated note holder warrants, Prior to repricing		3 years 3 months 18 days
Impact of repricing subordinated note holder warrants, After pricing		3 years 3 months 18 days
Transfer from liability to equity		4 years 9 months 18 days
Exercisable, weighted average remaining contractual life		3 years 4 months 24 days
Liability Warrants [Member]
Shares Under Warrants [Roll Forward]
Outstanding at beginning of period (in shares)	0	4,474,868	726,489
Issued (in shares)		11,783,163	2,685,000
Impact of repricing senior lender warrants, Prior to repricing (in shares)			(300,000)
Impact of repricing senior lender warrants, After repricing (in shares)			300,000
Impact of repricing senior lender warrants, Prior to repricing (in shares)			(300,000)
Impact of repricing senior lender warrants, After repricing (in shares)			300,000
Impact of repricing senior debenture purchaser warrants, Prior to repricing (in shares)		0
Impact of repricing senior debenture purchaser warrants, After repricing (in shares)		0
Impact of repricing subordinated note holder warrants, Prior to repricing (in shares)		0
Impact of repricing subordinated note holder warrants, After repricing (in shares)		0
Impact of anti-dilution clauses, Prior to impact (in shares)		(1,489,868)	(426,489)
Impact of anti-dilution clauses, After impact (in shares)		2,327,919	1,489,868
Transfer from liability to equity (in shares)		(14,768,163)
Exercised (in shares)		(2,327,919)	0
Forfeited, expired or cancelled (in shares)		0	0
Outstanding at end of period (in shares)		0	4,474,868	726,489
Exercisable at end of period (in shares)		0
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)	$ 0	$ 1.82	$ 5.24
Issued (in dollars per share)		0.96	2.03
Impact of repricing senior lender warrants, Prior to repricing (in dollars per share)			5.25
Impact of repricing senior lender warrants, After repricing (in dollars per share)			1.80
Impact of repricing senior lender warrants, Prior to repricing (in dollars per share)			1.80
Impact of repricing senior lender warrants, After repricing (in dollars per share)			1.60
Impact of anti-dilution clauses, Prior to impact (in dollars per share)		1.50	5.24
Impact of anti-dilution clauses, After impact (in dollars per share)		0.96	1.50
Transfer from liability to equity (in dollars per share)		1.16
Exercised (in dollars per share)		0.96
Outstanding at end of period (in dollars per share)		0	$ 1.82	$ 5.24
Exercisable at end of period (in dollars per share)		$ 0
Equity and Liability Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life		0 years	3 years 3 months 18 days	2 years 10 months 24 days
Issued		5 years	5 years
Impact of repricing senior lender warrants, Prior to repricing			3 years 10 months 24 days
Impact of repricing senior lender, After repricing			3 years 10 months 24 days
Impact of repricing senior lender warrants, Prior to repricing			3 years 8 months 12 days
Impact of repricing senior lender, After repricing			3 years 8 months 12 days
Impact of anti-dilution clauses, Prior to impact		9 months 18 days	1 year 9 months 18 days
Impact of anti-dilution clauses, After impact		9 months 18 days	1 year 9 months 18 days
Transfer from liability to equity		4 years 9 months 18 days
Exercised		0 years
Exercisable, weighted average remaining contractual life		0 years

EQUITY, SHARE-BASED COMPENSAT53

EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONS, Transactions with Holders (Details) - USD ($) $ / shares in Units, $ in Thousands	Feb. 28, 2017	Jul. 31, 2017	Feb. 28, 2017	Feb. 29, 2016	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Jan. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares)					21,157,273	10,838,978
Proceeds from issuance of preferred stock and warrants, net of issuance costs					$ 1,747	$ 2,554
Loss on extinguishment of debt		$ (6,600)			(8,290)	0
Dividends on preferred stock					0	0
Proceeds from issuance of debt and warrants, net of issuance costs					5,518	300
Repayment of debt					$ 19,744	$ 32,344
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares)	2,327,919		2,327,919	1,489,868						426,489
Exercise price per warrant (in dollars per share)	$ 0.96		$ 0.96	$ 1.50						$ 5.24
Common stock issued (in shares)			614,610
Weighted average grant date fair value (in dollars per share)			$ 1.38
Recorded loss on issuance of common stock			$ (100)
Warrants [Member] | Expiration February, 2022 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares)	1,423,488		1,423,488
Exercise price per warrant (in dollars per share)	$ 0.96		$ 0.96
Warrants [Member] | Expiration August, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares)				2,660,000
Exercise price per warrant (in dollars per share)				$ 2
Proceeds allocated to derivative warrant liability				$ 2,500
Lender [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per warrant (in dollars per share)							$ 1.60	$ 1.85		$ 5.25
Series G Convertible Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock issued (in shares)	2,000		2,000		630
Debt conversion amount	$ 100
Debt conversion, stock (in shares)	180
Net proceeds from the exchange of subordinated notes	$ 1,700
Cash offering expenses	100
Proceeds allocated to derivative warrant liability	1,000
Warrants recorded at fair value	100
Loss on extinguishment of debt	(100)
Decrease in subordinated debt	(100)
Proceed recorded as preferred stock	1,200
Recorded dividend for preferred stock	$ 800
Series F Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock issued (in shares)				3,000	0
Dividends on preferred stock				$ 500
Fair value of common stock issued				2,700
Series F Preferred Stock [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Underwriters cash fee				200
Proceeds from issuance of preferred stock and warrants, net of issuance costs				2,600
Warrants offering expenses				400
Gross proceeds				$ 3,000
Subordinated Debt [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares)	3,484,675		3,484,675
Exercise price per warrant (in dollars per share)	$ 0.96		$ 0.96
Loss on extinguishment of debt			$ (1,500)
Decrease in subordinated debt			(900)
Fair value of derivative warrant liabilities			2,300
Fair value increase in common stock			$ 100
Annual interest rate	7.00%		7.00%			11.75%
Repayment of debt			$ 500
Subordinated Debt [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price per warrant (in dollars per share)	$ 0.96		$ 0.96			$ 5.25
Amendment of existing warrants (in shares)			289,669
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate principal amount									$ 300
Director [Member] | Warrants [Member] | Expiration January, 2021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares)									25,000
Exercise price per warrant (in dollars per share)									$ 5.25
Senior Secured Debt [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from issuance of debt and warrants, net of issuance costs			$ 5,500
Placement fees and allocation expenses			$ 500
Warrants exercisable term					2 years 1 month 6 days
Senior Secured Debt [Member] | Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants to purchase shares of common stock (in shares)	6,875,000		6,875,000
Exercise price per warrant (in dollars per share)	$ 0.96		$ 0.96
Aggregate subscription amount	$ 6,000		$ 6,000
Aggregate principal amount	$ 6,600		$ 6,600
Amendment of existing warrants (in shares)			875,000
Exercise price per warrant one (in dollars per share)	$ 5.49		$ 5.49
Warrants exercisable term					5 years 6 months
Fair value of derivative warrant liabilities			$ 4,600
Fair value increase in common stock			500
Debt issuance cost	$ 400		400
Extinguishment of term loan			3,800
Repayment of subordinated note			200
Interest expense debt			$ 300

EQUITY, SHARE-BASED COMPENSAT54

EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONS, Other Equity Issuances and Adjustments (Details) - USD ($)	Feb. 28, 2017	Jan. 31, 2018	Sep. 30, 2017	Aug. 31, 2017	Jun. 30, 2017	Feb. 28, 2017	Feb. 29, 2016	Mar. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Other Equity Issuances and Adjustments [Abstract]
Cash paid in lieu of bonus											$ 0
Proceeds from sale of common stock, net of costs										$ 2,730,000
Common Stock [Member]
Other Equity Issuances and Adjustments [Abstract]
Common stock issued for employee (in shares)											950,000
Cash paid in lieu of bonus											$ 0
Proceeds from sale of common stock, net of costs (in shares)			2,654,732							2,654,732
Stock price (in dollars per share)			$ 1.08
Proceeds from sale of common stock, net of costs			$ 2,800,000							$ 2,730,000
Cash offering expenses			$ 100,000
Preferred shares converted into common stock (in shares)										3,300,118
Supplier [Member] | Common Stock [Member]
Other Equity Issuances and Adjustments [Abstract]
Common stock issued for employee (in shares)							950,000
Fixed price per share held in escrow by supplier (in dollars per share)							$ 2.80
Shares released from escrow (in shares)										59,292
Consultant [Member] | Common Stock [Member] | Subsequent Event [Member]
Other Equity Issuances and Adjustments [Abstract]
Common stock issued for employee (in shares)		14,129
Stock price (in dollars per share)		$ 1.38
Series F Convertible Preferred Stock [Member]
Other Equity Issuances and Adjustments [Abstract]
Preferred shares converted into common stock (in shares)										499
Series F Convertible Preferred Stock [Member] | Common Stock [Member]
Other Equity Issuances and Adjustments [Abstract]
Preferred shares converted into common stock (in shares)										986,491
Carrying value of preferred stock to reclassified common stock										$ 400,000
Series G Convertible Preferred Stock [Member]
Other Equity Issuances and Adjustments [Abstract]
Cash offering expenses	$ 100,000
Preferred shares converted into common stock (in shares)										670
Former Employee [Member]
Other Equity Issuances and Adjustments [Abstract]
Common stock issued for employee (in shares)						108,696
Cash paid in lieu of bonus						$ 100,000
Board of Directors Chairman [Member]
Other Equity Issuances and Adjustments [Abstract]
Shares issued (in shares)					96,372
Transitional monthly compensation awarded								$ 8,333	$ 10,000
Transitional monthly compensation awarded in lieu of cash (in shares)								9,027	7,035
Director [Member]
Other Equity Issuances and Adjustments [Abstract]
Shares issued (in shares)				35,336	345,205
Grant date fair value (in dollars per share)				$ 1.09	$ 0.90
Employee [Member] | Common Stock [Member] | Subsequent Event [Member]
Other Equity Issuances and Adjustments [Abstract]
Common stock issued for employee (in shares)		50,469
Stock price (in dollars per share)		$ 1.38

EQUITY, SHARE-BASED COMPENSAT55

EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONS, Equity Incentive Plan (Details) - 2014 Plan [Member] - shares	1 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2017	May 31, 2017
Company Plan [Abstract]
Initially reserved (in shares)		3,300,000	1,600,000
Increase in shares authorized (in shares)	1,700,000
Term of options		10 years
Options granted to purchase common stock (in shares)		3,081,674
Common stock reserved for future issuance (in shares)		218,326

EQUITY, SHARE-BASED COMPENSAT56

EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONS, Options (Details) - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Shares Under Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)	170,811	357,797
Granted (in shares)	481,500	0
Exercised (in shares)	0	0
Forfeited, expired or cancelled (in shares)	(12,652)	(186,986)
Outstanding at end of period (in shares)	639,659	170,811	357,797
Options, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)	$ 8.83	$ 12.12
Granted (in dollars per share)	0.79
Forfeited, expired or cancelled (in dollars per share)	3.62	8.88
Outstanding at end of period (in dollars per share)	$ 2.91	$ 8.83	$ 12.12
Options, Weighted Average Remaining Contractual Life [Abstract]
Outstanding, weighted average remaining contractual life	8 years 6 months	7 years 2 months 12 days	7 years 10 months 24 days
Granted	10 years
Forfeited, expired or cancelled	8 years 1 month 6 days	6 years 6 months
Intrinsic value of options outstanding	$ 300
Weighted average remaining vesting period	3 years 9 months 18 days
Unrecognized compensation cost of stock options	$ 200
Fair value of options granted (in dollars per share)	$ 2.68
Weighted-average assumptions used in valuing stock options [Abstract]
Assumed volatility, minimum	85.00%
Assumed volatility, maximum	87.00%
Assumed volatility, weighted average	87.00%
Assumed risk free interest rate, minimum	1.80%
Assumed risk free interest rate, maximum	2.00%
Assumed risk free interest rate, weighted average	2.00%
Average expected life of options	6 years 2 months 12 days
Expected dividends	$ 0
Weighted Average [Member]
Weighted-average assumptions used in valuing stock options [Abstract]
Average expected life of options	6 years 2 months 12 days

EQUITY, SHARE-BASED COMPENSAT57

EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONS, Range of Exercise Price (Details) - Stock Options [Member]	1 Months Ended	12 Months Ended
	Jan. 31, 2018Installment$ / sharesshares	Dec. 31, 2017$ / sharesshares	Dec. 31, 2016shares
Summary of Information Related to Outstanding and Exercisable Stock Options [Abstract]
Shares underlying options, outstanding (in shares) | shares		639,659
Weighted average exercise price, outstanding (in dollars per share)		$ 2.91
Weighted average remaining contractual life, outstanding		8 years 6 months
Shares underlying options, exercisable (in shares) | shares		209,862
Weighted average exercise price, exercisable (in dollars per share)		$ 7.06
Weighted average remaining contractual life, exercisable		6 years 9 months 18 days
Common stock issued for stock option exercises (in shares) | shares		481,500	0
Employee [Member] | Subsequent Event [Member]
Summary of Information Related to Outstanding and Exercisable Stock Options [Abstract]
Exercise price of stock options (in dollars per share)	$ 1.42
Weighted average grant date fair value of stock options (in dollars per share)	$ 0.97
Number of equal annual installments | Installment	4
Maximum [Member] | Employee [Member] | Subsequent Event [Member]
Summary of Information Related to Outstanding and Exercisable Stock Options [Abstract]
Common stock issued for stock option exercises (in shares) | shares	278,873
$0.76 to $0.91 [Member]
Summary of Information Related to Outstanding and Exercisable Stock Options [Abstract]
Exercise price range, lower range limit (in dollars per share)		$ 0.76
Exercise price range, upper range limit (in dollars per share)		$ 0.91
Shares underlying options, outstanding (in shares) | shares		450,500
Weighted average exercise price, outstanding (in dollars per share)		$ 0.83
Weighted average remaining contractual life, outstanding		9 years 3 months 18 days
Shares underlying options, exercisable (in shares) | shares		53,332
Weighted average exercise price, exercisable (in dollars per share)		$ 0.79
Weighted average remaining contractual life, exercisable		9 years 2 months 12 days
$1.09 to $1.98 [Member]
Summary of Information Related to Outstanding and Exercisable Stock Options [Abstract]
Exercise price range, lower range limit (in dollars per share)		$ 1.09
Exercise price range, upper range limit (in dollars per share)		$ 1.98
Shares underlying options, outstanding (in shares) | shares		31,000
Weighted average exercise price, outstanding (in dollars per share)		$ 1.27
Weighted average remaining contractual life, outstanding		9 years 4 months 24 days
Shares underlying options, exercisable (in shares) | shares		5,000
Weighted average exercise price, exercisable (in dollars per share)		$ 1.98
Weighted average remaining contractual life, exercisable		7 years 10 months 24 days
$2.91 to $2.97 [Member]
Summary of Information Related to Outstanding and Exercisable Stock Options [Abstract]
Exercise price range, lower range limit (in dollars per share)		$ 2.91
Exercise price range, upper range limit (in dollars per share)		$ 2.97
Shares underlying options, outstanding (in shares) | shares		19,000
Weighted average exercise price, outstanding (in dollars per share)		$ 2.97
Weighted average remaining contractual life, outstanding		7 years 7 months 6 days
Shares underlying options, exercisable (in shares) | shares		14,828
Weighted average exercise price, exercisable (in dollars per share)		$ 2.97
Weighted average remaining contractual life, exercisable		7 years 7 months 6 days
$3.47 [Member]
Summary of Information Related to Outstanding and Exercisable Stock Options [Abstract]
Exercise price range, upper range limit (in dollars per share)		$ 3.47
Shares underlying options, outstanding (in shares) | shares		34,790
Weighted average exercise price, outstanding (in dollars per share)		$ 3.47
Weighted average remaining contractual life, outstanding		7 years 6 months
Shares underlying options, exercisable (in shares) | shares		32,429
Weighted average exercise price, exercisable (in dollars per share)		$ 3.47
Weighted average remaining contractual life, exercisable		7 years 6 months
$4.27 to $6.00 [Member]
Summary of Information Related to Outstanding and Exercisable Stock Options [Abstract]
Exercise price range, lower range limit (in dollars per share)		$ 4.27
Exercise price range, upper range limit (in dollars per share)		$ 6
Shares underlying options, outstanding (in shares) | shares		55,243
Weighted average exercise price, outstanding (in dollars per share)		$ 4.63
Weighted average remaining contractual life, outstanding		6 years 7 months 6 days
Shares underlying options, exercisable (in shares) | shares		55,147
Weighted average exercise price, exercisable (in dollars per share)		$ 4.83
Weighted average remaining contractual life, exercisable		6 years 7 months 6 days
$16.00 [Member]
Summary of Information Related to Outstanding and Exercisable Stock Options [Abstract]
Exercise price range, upper range limit (in dollars per share)		$ 16
Shares underlying options, outstanding (in shares) | shares		42,335
Weighted average exercise price, outstanding (in dollars per share)		$ 16
Weighted average remaining contractual life, outstanding		3 years 10 months 24 days
Shares underlying options, exercisable (in shares) | shares		42,335
Weighted average exercise price, exercisable (in dollars per share)		$ 16
Weighted average remaining contractual life, exercisable		3 years 10 months 24 days
$28.00 to $74.00 [Member]
Summary of Information Related to Outstanding and Exercisable Stock Options [Abstract]
Exercise price range, lower range limit (in dollars per share)		$ 28
Exercise price range, upper range limit (in dollars per share)		$ 74
Shares underlying options, outstanding (in shares) | shares		6,791
Weighted average exercise price, outstanding (in dollars per share)		$ 49.94
Weighted average remaining contractual life, outstanding		3 years 7 months 6 days
Shares underlying options, exercisable (in shares) | shares		6,791
Weighted average exercise price, exercisable (in dollars per share)		$ 49.94
Weighted average remaining contractual life, exercisable		3 years 7 months 6 days

EQUITY, SHARE-BASED COMPENSAT58

EQUITY, SHARE-BASED COMPENSATION, WARRANTS AND FINANCING TRANSACTIONS, Restricted Stock Units (Details) - USD ($)		1 Months Ended				12 Months Ended
		Jan. 31, 2018		Jun. 30, 2017	Nov. 30, 2016	Dec. 31, 2017		Dec. 31, 2016		Dec. 31, 2015
Weighted Average Remaining Vesting and Unrecognized Stock Compensation [Abstract]
Weighted average remaining vesting						3 years 4 months 24 days		2 years 9 months 18 days
Restricted Stock Units [Member] | Supplier [Member]
Weighted Average Remaining Vesting and Unrecognized Stock Compensation [Abstract]
Shares issued to supplier, nonvested and unearned (in shares)						890,708
Fixed price per share held in escrow by supplier (in dollars per share)						$ 2.80
Restricted Stock Units [Member] | Employees and Director [Member]
Restricted Stock Award Activity, Number [Roll Forward]
Beginning balance, Nonvested (in shares)		384,744	[1]			256,839		324,229
Granted (in shares)						380,541		174,825
Vested (in shares)						(252,636)	[2]	(242,215)	[3]
Forfeited (in shares)						0		0
Ending balance, Nonvested (in shares)						384,744	[1]	256,839		324,229
Restricted Stock Award Activity, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance, Nonvested (in dollars per share)		$ 0.94				$ 2.44		$ 4.25
Granted (in dollars per share)						0.92		1.46
Vested (in dollars per share)						2.42		4.16
Ending balance, Nonvested (in dollars per share)						$ 0.94		$ 2.44		$ 4.25
Restricted Stock Award Activity, Fair Value [Abstract]
Granted, Fair Value	[4]					$ 349,000		$ 255,000
Vested, Fair Value	[4]					220,000		323,000
Nonvested, Fair Value	[4]					$ 569,000		$ 265,000		$ 616,000
Weighted Average Remaining Vesting and Unrecognized Stock Compensation [Abstract]
Weighted average remaining vesting						6 months		8 months 12 days		1 year 7 months 28 days
Unrecognized stock compensation						$ 176,300		$ 284,600		$ 796,300
Restricted Stock Units [Member] | Employees and Director [Member] | Employee Severance [Member]
Restricted Stock Award Activity, Number [Roll Forward]
Vested (in shares)				(73,608)	(147,836)
2014 Plan [Member] | Restricted Stock Units [Member]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Line Items]
Common stock issued (in shares)				1,175,000
Number of trading days						65 days
Grant date fair value				$ 200,000
Expensed ratably term						3 years 6 months
2014 Plan [Member] | Vesting Price Equals or Exceeds $5.00 [Member] | Restricted Stock Units [Member]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Line Items]
Vesting percentage				10.00%
Vesting price (in dollars per share)				$ 5
2014 Plan [Member] | Vesting Price Equals or Exceeds $10.00 [Member] | Restricted Stock Units [Member]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Line Items]
Vesting percentage				30.00%
Vesting price (in dollars per share)				$ 10
2014 Plan [Member] | Vesting Price Equals or Exceeds $15.00 [Member] | Restricted Stock Units [Member]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Line Items]
Vesting percentage				60.00%
Vesting price (in dollars per share)				$ 15
2014 Plan [Member] | Vesting Price Equals or Exceeds $15.00 [Member] | Restricted Stock Units [Member] | Subsequent Event [Member]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Line Items]
Cancelled percentage		60.00%
Cancelled vesting price (in dollars per share)		$ 15
[1]	Excludes 890,708 shares, issued to a supplier, nonvested and unearned as of December 31, 2017. The shares are being held in escrow until earned (as defined in our agreement) by the supplier at a fixed price of $2.80 per share
[2]	Includes 73,608 shares, for which vesting was accelerated in June 2017, based on the terms of a severance agreement.
[3]	Includes 147,836 shares, for which vesting was accelerated in November 2016, based on the terms of a severance agreement.
[4]	Represents pre-tax fair value, based on our closing stock prices, which would have been received by the holders of the stock had all such holders sold their underlying shares on the date indicated, the dates of grant or the dates of vesting, as applicable.

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
INCOME TAXES [Abstract]
Change in tax rate, income tax expense (benefit)			$ 7,100
Components of Deferred Tax Asset (Liability) [Abstract]
Net operating loss carryforwards					$ 5,560	$ 7,946
Capital loss					7,030	363
Stock options and warrants					322	724
Property					499	743
Intangible assets					89
Intangible assets						(252)
Capitalized expenses					142	342
Debt and deferred financing					0	178
Other					230	466
Net deferred tax assets					13,872	10,510
Less: Valuation allowance		$ (13,872)	(13,872)	$ (10,510)	(13,872)	(10,510)
Deferred tax asset (liability)					0	$ 0
Summary of Changes in Valuation Allowance [Roll Forward]
Valuation allowances at beginning of year		$ 13,872	10,510	5,726
Net operating loss			4,358	5,021
Expiration of net operating losses and limitations			2,353	(105)
Effect of federal rate reduction from 34% to 21%			(7,079)	0
Capital loss from redemption of Nutra SA interests			11,058	0
Other adjustments			(1,384)	(132)
Change in valuation allowance, before transfer			9,306	4,784
Transferred from discontinued operations			(5,944)	0
Valuation allowances at end of year			$ 13,872	$ 10,510
Income Tax Disclosure [Line Items]
Federal statutory income tax rate			34.00%	34.00%
Operating Loss Carryforwards [Line Items]
Capital loss carryforward					29,100
Minimum percentage of interest in value of equity by new shareholder	5.00%
Current [Abstract]
State			$ 16	$ 45
Deferred [Abstract]
Federal			(4,684)	(1,732)
State			(362)	(137)
Total deferred			(5,046)	(1,869)
Income tax benefit			(5,030)	(1,824)
Income Tax Reconciliation [Abstract]
Income tax benefit at federal statutory rate			(5,173)	(2,704)
Increase (decrease) resulting from [Abstract]
State tax benefit, net of federal tax effect			(400)	(214)
Effect of federal rate reduction from 34% to 21%			7,079	0
Change in valuation allowance			9,306	4,784
Capital loss from redemption of Nutra SA interests			(11,058)	0
Expiration of net operating losses			(310)	105
Reduction in deferred balances for forfeited, expired or cancelled options			317	168
Nontaxable fair value adjustment			(234)	(553)
Nondeductible expenses			55	(465)
Other adjustments to deferred balances			0	(994)
Allocated from discontinued operations			(5,046)	(1,864)
Other			434	(86)
Income tax benefit			$ (5,030)	$ (1,824)
Plan [Member]
Income Tax Disclosure [Line Items]
Federal statutory income tax rate		21.00%
Federal [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards					22,500
Federal [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates			Dec. 31, 2021
Federal [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates			Dec. 31, 2037
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards					$ 15,600
State [Member] | Minimum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates			Dec. 31, 2018
State [Member] | Maximum [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration dates			Dec. 31, 2037

FAIR VALUE MEASUREMENT (Details

FAIR VALUE MEASUREMENT (Details) - Derivative Warrant Liability [Member] - Recurring [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	$ 1,527
Additional assumptions used to calculate fair value [Abstract]
Expected volatility	64.00%
Minimum [Member]
Additional assumptions used to calculate fair value [Abstract]
Risk-free interest rate	0.60%
Maximum [Member]
Additional assumptions used to calculate fair value [Abstract]
Risk-free interest rate	1.90%
Weighted Average [Member]
Additional assumptions used to calculate fair value [Abstract]
Risk-free interest rate	1.60%
Expected volatility	64.00%
Level 1 [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	$ 0
Level 2 [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	0
Level 3 [Member]
Fair values by input hierarchy of items measured at fair value on a recurring basis [Abstract]
Total liabilities at fair value	$ 1,527

FAIR VALUE MEASUREMENT, Unobser

FAIR VALUE MEASUREMENT, Unobservable Input Reconciliation (Details) - Recurring [Member] - Derivative Warrant Liability [Member] - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016
Changes in level 3 items measured at fair value on a recurring basis [Roll Forward]
Fair Value as of Beginning of Year		$ (1,527)	$ (678)
Total Realized and Unrealized Gains (Losses)	[1]	669	1,625
Issuance of New Instruments		(7,917)	(2,474)
Reclassify to Equity (Deficit)		7,980	0
Conversion to Common Stock		795	0
Fair Value, at End of Year		0	(1,527)
Gains (Losses) on Instruments Still Held		$ 0	$ (849)
[1]	Included in change in fair value of derivative warrant liabilities in net income (loss).

COMMITMENTS AND CONTINGENCIES62

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	Mar. 15, 2018USD ($)ft²	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Leases [Abstract]
Remaining term of lease		16 years
Rent expense		$ 400	$ 600
Future minimum payments under operating lease commitments [Abstract]
2,018		386
2,019		377
2,020		384
2,021		394
2,022		404
Thereafter		2,336
Total minimum lease payments		4,281
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual [Line Items]
Severance payments		$ 400	300
Severance expense			$ 700
Subsequent Event [Member]
Operating Leased Assets [Line Items]
Area of office space under lease | ft²	5,380
Initial term of lease	65 months
Term of rent abated	5 months
Rent expense for base rent	$ 100
Additional extension to lease term	5 years

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)	1 Months Ended		6 Months Ended	12 Months Ended
	Sep. 30, 2017Nomineeshares	Jul. 31, 2017USD ($)shares	Jun. 30, 2017	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Jul. 31, 2016
Related Party Transaction [Line Items]
Interest paid				$ 811,000	$ 1,849,000
Interest expense				1,623,000	2,483,000
LF-RB Group [Member]
Related Party Transaction [Line Items]
Ownership interest percentage						9.00%
Legal fees and other expenses paid in cash		$ 50,000
Legal fees and other expense paid in shares (in shares) | shares		100,000
Continental Grain Company [Member]
Related Party Transaction [Line Items]
Sale of common stock (in shares) | shares	2,654,732
Percentage of outstanding debt retained by related party	16.00%
Number of nominee for the Board of Directors related party can designate | Nominee	1
Baruch Halpern [Member]
Related Party Transaction [Line Items]
Percentage of outstanding debt retained by related party			43.00%
Baruch Halpern [Member] | Subordinated Notes [Member]
Related Party Transaction [Line Items]
Interest paid				200,000	300,000
Interest expense				$ 100,000	$ 300,000

FAILURE TO COMPLY WITH NASDAQ64

FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016	Aug. 18, 2016	Dec. 31, 2015
FAILURE TO COMPLY WITH NASDAQ LISTING REQUIREMENTS [Abstract]
Nasdaq minimum stockholders' equity listing requirement				$ 2,500
Stockholders' equity (deficit)	$ 14,733	$ 7,900	$ (632)		$ 7,268
Nasdaq minimum bid price requirement (in dollars per share)	$ 1
Number of consecutive business days under minimum bid requirement, out of compliance	30 days
Nasdaq grant of extension period to regain compliance under minimum stockholders' equity requirement	180 days
Number of consecutive business days at minimum bid price to regain compliance	10 days

GAIN ON RESOLUTION OF IRGOVEL65

GAIN ON RESOLUTION OF IRGOVEL PURCHASE LITIGATION (Details) - USD ($) $ in Thousands	Mar. 24, 2016	Dec. 31, 2017	Dec. 31, 2016	Jan. 31, 2008
Loss Contingencies [Line Items]
Gain recognized from contingencies		$ 0	$ 1,598
Sellers [Member]
Loss Contingencies [Line Items]
Amount held in escrow				$ 2,000
Amount of escrow released	$ 1,900
Gain recognized from contingencies			1,600
Amount of escrow liability in accrued expenses			1,900
Pre-acquisition contingencies			$ 300
Repayment of term note		$ 1,000